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Triple-negative breast cancers (TNBC) are characterized by the lack of or reduced 
expression of the estrogen and progesterone receptors, and normal expression of the 
human epidermal growth factor receptor 2. The lack of a well-characterized target for 
treatment leaves only systemic chemotherapy as the mainstay of treatment. 
Approximately 60-70% of patients are chemosensitive, while the remaining majority 
does not respond. Targeted therapies that take advantage of the unique molecular 
perturbations found in triple-negative breast cancer are needed. The genes that are 
frequently amplified or overexpressed represent potential therapeutic targets for triple-
negative breast cancer. The purpose of this study was to identify and validate novel 
therapeutic targets for triple-negative breast cancers. 
681 genes showed consistent and highly significant overexpression in TNBC 
compared to receptor-positive cancers in 2 data sets. For two genes, 3 of the 4 siRNAs 
showed preferential growth inhibition in TNBC cells. These two genes were the low 
density lipoprotein receptor-related protein 8 (LRP8) and very low-density lipoprotein 
receptor (VLDLR). Exposure to their cognate ligands, reelin and apolipoprotein E 
isoform 4 (ApoE4), stimulated the growth of TNBC cells in vitro. Suppression of the 
vii 
 
expression of either LRP8 or VLDLR or exposure to RAP (an inhibitor of ligand binding 
to LRP8 and VLDLR) abolished this ligand-induced proliferation. High-throughput 
protein and metabolic arrays revealed that ApoE4 stimulation rescued TNBC cells from 
serum-starvation induced up-regulation of genes involved in lipid biosynthesis, increased 
protein expression of oncogenes involved in the MAPK/ERK and DNA repair pathways, 
and reduced the serum-starvation induction of biochemicals involved in oxidative stress 
response and glycolytic metabolism. shLRP8 MDA-MB-231 xenografts had reduced 
tumor volume, in comparison to parental and shCON xenografts. These results indicate 
that LRP8-APOE signaling confers survival advantages to TNBC tumors under reduced 
nutrient conditions and during cellular environmental stress.  
We revealed that the LRP8-APOE receptor-ligand system is overexpressed in 
human TNBC. We also demonstrated that this receptor system mediates a strong growth 
promoting and survival function in TNBC cells in vitro and helps to sustain the growth of 
MDA-MD-231 xenografts. We propose that inhibitors of LRP8-APOE signaling may be 
clinically useful therapeutic agents for triple-negative breast cancer. 
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1.1. Triple-negative breast cancer 
 Approximately 20% of all breast cancers are referred to as triple-negative breast 
cancers, which lack the immunohistochemical expression of the estrogen and 
progesterone receptors and of the human epidermal growth factor receptor 2, HER2 (1). 
Currently, effective treatment options are limited to chemotherapy, but the majority of 
patients who fail to achieve pathologic complete response after chemotherapy has 
unfavorable prognosis (2, 3). Therapeutics that target the unique molecular features of 
TNBC are needed.  
 
1.2. Common molecular alterations 
 Triple-negative breast cancer (TNBC) is characterized by the lack of or reduced 
expression of the estrogen and progesterone receptor (ER and PR), and normal 
expression of the human epidermal growth factor receptor 2 (HER2) (2, 3). This 
convenient naming system is based on routing immunohistochemistry performed in the 
clinic. It is also referred to as the basal-like breast cancers due to the expression of basal 
epithelial cell type markers and is one of the five intrinsic breast cancer subtypes 
distinguished on the basis of their gene expression patterns (2, 3). However, the overlap 
between the two different identification systems is approximately 80%, with discordance 
in the expression of basal markers, immune response markers, and types of p53 mutation 
(4-8). 15-40% of TNBC tumors have BRCA-related epigenetic down-regulation and 
increased expression of the inhibitors of BRCA1 function (9). This indicates that the label 
“triple-negative breast cancer” describes a more heterogeneous subtype than other breast 
cancer subtypes (10, 11).  
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Triple-negative breast cancers are differentiated from receptor-positive breast 
cancers by large-scale DNA copy number changes and gene expression differences (5, 
12). Key mediators of immunological response, proliferation, and neuronal signaling, 
such as MYC, LYN, EGFR, and CEBPB, are either amplified or overexpressed in TNBC 
in comparison to other breast cancer subtypes (13). These differences reflect the unique 
molecular landscape of triple-negative breast cancers and represents potential therapeutic 
targets that require experimental validation.  
 Human gene expression profiling provides the opportunity to start the target 
identification process in human triple-negative breast cancers (4, 5). Consistently 
observed genomic abnormalities have specific roles in the proliferation of breast tumors, 
such as dysregulation of the estrogen receptor (ER) in ER+ disease and overexpression of 
the human epidermal growth factor receptor-2 (HER2) in HER2+ disease (5). Results 
from high-throughput microarray analyses have revealed large-scale gene expression and 
DNA copy number pattern differences between these clinical subsets of breast cancers (5-
8). The distinct genomic differences have important clinical implications for patient 
outcome. These molecular differences may be the source of potential novel therapeutic 
targets for unsuccessfully targeted subsets, such as triple-negative breast cancer (7, 9, 13). 
Experimental and empirical validation of the various potential therapeutic targets 
identified in human genomic data is central to future treatment success in the clinic. 
 
1.3. Clinicopathologic features of patient population 
 There are aggressive clinical features that typify patients with triple-negative 
breast disease. Younger age of disease onset and women of African or Hispanic descent 
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have been associated with higher rates of triple-negative disease. An increased proportion 
of TNBC patients have higher rates of CNS, visceral, and bony metastases and overall 
poor outcome despite therapeutic treatment (2). This metastatic phenotype of TNBC is 
due in part to the high nuclear grade of TNBC tumors and results in shorter time to 
disease recurrence and shorter median survival time in of advanced metastatic TNBC (1, 
2).  
 The TNBC paradox details that there is a high proportion of responsive patients 
that exhibit pathologic complete response to neoadjuvant chemotherapy, while the 
survival (both disease-free and overall) of the entire basal-like group was significantly 
worse in comparison to the luminal or ER-associated subtypes (1, 2). However, this 
worse overall survival is comprised of patients with residual cancer (1, 2). 
 
1.4. Existing chemotherapeutic treatment options and targeted therapies 
  Currently, treatment options are limited to conventional chemotherapy with 
limited long-term success (1, 2). Two-thirds of patients are chemosensitive, while the 
remaining portion of patients does not respond to chemotherapy. TNBC patients have a 
better response to chemotherapy in the neoadjuvant setting, in comparison to non-TNBC 
patients (1, 2). TNBC patients that are initially non-responsive have higher relapse risk 
and worse overall survival at 68% than responders who exhibit pathologic complete 
response at 94% overall survival (14). Non-TNBC or receptor-positive breast cancers 
with residual disease have the benefit of selective estrogen receptor modulators and 
trastuzumab (14).  
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In light of the heterogeneous nature of TNBC and lack of targeted therapy 
options, several classes of targeted therapeutics have been tested to provide non-
responsive patients with a therapeutic alternative. Epidermal growth factor receptor 
(EGFR) has been identified as a frequently overexpressed marker in triple-negative breast 
cancer (15). anti-EGFR agents such as the monoclonal antibody cetuximab have resulted 
in a minimal efficacy in retrospective and prospective studies (16). BALI-1, the largest 
EGFR clinical trial to date that is testing the combination of cetuximab and cisplatin, did 
not result in improved overall recurrence or overall survival rates (16). The combination 
of cetuximab to carboplatin and irinotecan did not improve progression-free or overall 
survival. The combination of carboplatin and cetuximab increased extended progression-
free survival from 2 to 8 months, but the overall progression-free and overall survival 
data is still pending (16). 
Tyrosine-kinase inhibitors such as erlotinib and lapatinib have been tested with 
inconsistent results (17). Erlotinib with docetaxel and carboplatin neoadjuvant treatment 
resulted in a 40% pathologic complete response in TNBC patients (17). However, the 
combination of lapatinib with paclitaxel did not result in antitumor activity in metastatic 
TNBC patients (17).  
Laboratory studies suggested that upregulated mTOR levels result in increased 
sensitivity to mTOR inhibitors and initial clinical results yielded promising levels of 
activity (18). Inhibitors of the mammalian target of rapamycin (mTOR) such as 
everolimus have been tested with standard chemotherapy in TNBC patients (randomized 
Phase II) and did not significantly improve pathologic complete response (18, 19).  
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Angiogenesis inhibitors have been tested in the clinic with modest overall results. 
The Avastin and Docetaxel (AVADO) trial reduced risk of progression by 47%, while the 
combination of bevacizumab and chemotherapy in the Regimens in Bevacizumab for 
Breast Oncology (RiBBOn)-1 resulted in no benefit for TNBC patients (20, 21). The 
long-term disease-free and overall survival data of the National Surgical Adjuvant Breast 
and Bowel Project 40 (NSABP)-B40 and GeparQuinto trials combining bevacizumab and 
anthracycline-taxane are still pending, but preliminary results indicate significantly 
increased pCR in TNBC patients and no improvement in pCR rates respectively in the 
trials (20, 21). 
Poly (ADP-ribose) polymerase 1/2-inhibitors such as veliparib and olaparib have 
demonstrated activity in BRCA mutated breast cancer (34). However, the activity of 
PARP inhibitors has not been demonstrated in TNBC tumors without BRCA mutation 
(22). Further, dosing of paclitaxel and olaparib have been complicated by side effects 
(22).  
 
1.5. Central hypothesis and specific aims 
 Central hypothesis. There are frequently amplified or overexpressed genes in 
triple-negative breast cancer, which represent novel therapeutic targets. The goals of this 
study were to (i) identify candidate target genes from human genomic data, (ii) assess the 
effect on cancer cell proliferation in a custom siRNA screen in 18 breast cancer cell lines, 
and (iii) to validate the top tier siRNA hits as potential TNBC target genes through 
functional and mechanistic analyses (Figure 1). The low density lipoprotein receptor-
related protein 8 (LRP8) and very low density lipoprotein receptor (VLDLR) are 
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membrane receptor proteins that have well-characterized roles in cholesterol trafficking 
and lipid metabolism, as well as neuronal signaling during development and after 
traumatic brain injury (23, 24). In this current study, these 2 receptors were characterized 
for their functional roles in the growth of TNBC cells, in response to their cognate 
ligands, reelin and apolipoprotein E. This study examines the functional role of the ApoE 
– LRP8/VLDLR signaling axis in TNBC as mediators of lipid metabolism that are 
important in the growth and survival of triple-negative breast cancer. 
Specific aim 1. To identify amplified or overexpressed genes in triple-negative 
breast cancer as candidate target genes. The hypothesis that there are frequently amplified 
or overexpressed genes in triple-negative breast cancer was tested using bioinformatics 
analyses of 2 independent datasets of gene expression profiling on human breast cancers 
and matching CGH results on a subset of those tumors. 
Specific aim 2. To test how the proliferation of an 18 breast cancer cell line panel 
was affected after siRNA depletion of the previously identified candidate targets. The 
hypothesis that growth inhibition would be preferential to TNBC cell lines (n=10) vs. 
non-TNBC cell lines (n=8) was tested using 4 unique siRNAs against each candidate 
target.  
Specific aim 3. To identify signaling pathways and experimentally validate the 
functional importance of the potential target genes in triple-negative breast cancer in vitro 
and in vivo. The hypothesis that TNBC has a unique molecular biology and pathway 
signaling was tested in ligand stimulation assays, after which transcriptional profiling and 
metabolomics arrays were performed to identify global gene expression and metabolic 
patterns that drive TNBC tumor biology.  
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Figure 1. Target identification and validation strategy for the treatment of triple-
negative breast cancer. The research strategy is to start the target discovery process by 
molecularly interrogating human breast tumors, identify and validate target genes using 
experimental models of breast cancer, and bring back specific therapeutic agents for a 
molecularly defined patient population. The research strategy entails a complementary 
strategy to traditional laboratory testing and starts the discovery process in human cancer 
tissues, identify novel therapeutic targets through bioinformatics analysis of human breast 
cancer genome expression data, and assess the functional importance of these novel 
genes the laboratory. Some of the functionally important targets that may be identified 
can be inhibited with existing drugs and new therapeutic agents will need to be developed 
for others. 
 
 
 
 
 
 
 
  Target identification from                     Target validation with            Treatment for molecularly 
breast cancer genomic data         in vitro and in vivo models       defined patient subpopulation 
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1.6. High-throughput discovery of candidate targets for TNBC 
 Initial discovery of the candidate targets for TNBC were performed through 
bioinformatics analyses of 2 publicly available gene expression profiling datasets of 
human breast cancers (25, 26). After using an initial discovery dataset that was verified 
by the second validation dataset, 681 genes were identified as being significantly and 
highly overexpressed in TNBC vs. non-TNBC patients. These 681 candidate genes for 
TNBC therapy were submitted to a custom siRNA screen, in which 18 breast cancer cell 
lines were treated with 4 unique siRNAs against each gene to determine the growth 
inhibitory effect mediated by siRNA depletion of each candidate gene. A list of siRNAs 
that resulted in preferential growth inhibition of the TNBC cell line group (n=10) was 
compared to that of the non-TNBC cell line group (n=8). The top tier hits were binned 
according to number of siRNAs that resulted in growth inhibition of the candidate gene, 
with 3 of 4 siRNAs resulting in preferential TNBC growth inhibition being assigned as 
the most consistently reproducible inhibitory effect on growth (Dharmacon rational 
siRNA design for RNA interference). The two genes that occupied this top tier 
assignment were the low density lipoprotein receptor-related protein 8 (LRP8) and very 
low-density lipoprotein receptor (VLDLR).  
 
1.7. LRP8-APOE receptor-ligand system 
 The low density lipoprotein receptor-related protein 8 (LRP8) and very low-
density lipoprotein receptor (VLDLR) function together and separately and are members 
of the low density lipoprotein (LDL) receptor family which has a historically prominent 
role in the homeostatic management of lipid and cholesterol trafficking in the central 
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nervous system and the peripheral circulation of the human body (23, 24, 27). 
Dysfunction of the receptor family members has been implicated in the imbalance 
between extracellular and intracellular pools of cholesterol in the context of familial 
hypercholesterolemia and atherosclerotic disease (27). The structural motifs that are 
common to LDL receptor family members are (i) type A binding repeats of ~40 amino 
acids with 6 cysteine pairs which is the ligand-binding domain, (ii) type B repeats with 6 
pairs of cysteines, (iii) 50 amino acids with consensus peptide YWTD, (iv) a serine-
threonin rich region named the O-linked sugar domain, (v) a 20 amino acid 
transmembrane region, and (vi) a cytoplasmic region with a receptor internalization 
signal (27). 
 The ligand binding region regulates binding interactions between reelin and 
APOE (2 well-characterized ligands) to LDL receptor family members (23, 27). The 
seven type A LDL repeats (LA indicating LDL receptor type A) mediates folding through 
the paired cysteines that form cysteine bridges and enable negatively charged acidic Asp 
and Glu residues to interact with positively charged  residues on reelin and APOE (23, 
27). This process is concentrated in LA repeats 2-7 of the receptor (27). 
 LRP8, otherwise known as the apolipoprotein E receptor 2 (ApoER2), may have 
3, 4, 5, 7, or 8 type A binding repeats in its ligand binding depending on the species and 
tissue of origin (27). LRP8 is prone to distinct products due to differential transcriptional 
splicing (27). In humans, LRP8 has a more restricted expression profile and is found in 
the brain, testis, and placenta. VLDLR contains an eighth type A repeat and is expressed 
in the brain and throughout many tissue types in the periphery (23). 
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1.8. Role of LRP8 and APOE in traumatic brain injury, Alzheimer’s disease and 
hyperlipidemia 
 The interaction of LRP8 and VLDLR is well-documented after traumatic brain 
injury whereby they interact after binding reelin (28). Disabled-1, an intracellular adaptor 
protein, is phosphorylated after binding to the NPxY motifs of the receptors (29). The 
phosphorylation starts a kinase cascade the regulates motility and regeneration of injured 
neuronal cells (29). More recently, the ApoE4 allelle has been associated with earlier age 
of onset for Alzheimer’s disease (30). Studies suggest that binding of the ApoE4 isoform 
results in impaired synaptic plasticity by reducing ApoER2 expression and Reelin 
responsivity (30).  
 Alternatively, the two receptors also coordinate the uptake of extracellular 
cholesterol through APOE cholesterol-bound moieties that allows cholesterol to be 
metabolized for energy (27). The genotype-specific properties of ApoE4 are also seen 
here; people with one copy of the APOE ε4 allele have an increased risk of 
hypercholesterolemia and atherosclerosis, while the APOE ε2 allele increases the risk of 
hyperlipoproteinemia type III (30). This is related to the differential binding affinities of 
the protein isoforms of the alleles, whereby APOE4 has an increased binding affinity due 
to more positively charged residues which are available to LRP8 and VLDLR as a result 
of a single nucleotide polymorphism (Cys to Arg 130) (30). In contrast, APOE2 protein 
isoform has reduced binding affinity to its receptors (Arg to Cys 176) (30). 
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1.9. LRP8 and APOE in cancer 
 Ectopic expression of LRP8 in malignant lung carcinoma has been linked to 
aberrations on the 1p chromosomal arm (31). There is early evidence that ApoE inhibits 
invasion in melanoma cell lines by binding LRP1 and LRP8 on adjacent endothelial cells, 
which is regulated by a three membered miRNA group (32). This study describe that 
APOE, irrespective of isoform type, mediates metastasis and that increasing APOE 
expression can act as an antiangiogenic or antimetastatic treatment route. In 
neuroblastoma cell lines, Reelin acts as a chemoattractant and promotes dissemination of 
tumor cells (33). Alternatively, other studies have reported that VLDLR downregulation 
inhibits cell motility in mouse embryonic fibroblasts and the MCF-7 (ER+) breast cancer 
cell line (34). ApoE knockout mice, ApoE(-/-), have increased circulating cholesterol and 
therefore higher triglyceride levels (35). These mice also had increased tumor growth and 
lung metastases after injection of metastatic mammary cancer cells (35). 
A case-control study of gastric cancer cases revealed that having one copy of the 
APOE ε2 allele was associated with a 60% decreased incidence of gastric cancer (36). An 
eight biomarker model for the detection of bladder cancer contains APOE as a highly 
accurate marker for the diagnosis of bladder cancer. A meta-analysis of 3,835 subjects 
revealed that the APOE ε4 allele is associated with breast cancer from studies out of Asia, 
however the ε2 allele was not associated with breast cancer (37). There were no 
associations found in Caucasians (37). ApoE3 protein isoform has also been found in the 
tumor endothelial vasculature of prostate cancer patient samples and required for 
proliferation of ovarian cancer cells (38, 39). Conversely, one analysis of the Copenhagen 
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City Heart Study suggests that low LDL levels are associated with cancer risk, but that 
APOE polymorphisms are not associated with increased cancer risk (40).  
In 2010, Porrata-Doria et al. reported that the E4/E4 genotype was significantly 
associated with younger onset breast cancer (21-50 years) in a cohort of Puerto Rican 
women (41). These studies suggest that LRP8/VLDLR and APOE/reelin may have a role 
in breast cancer that is not yet understood.  
 
1.10. Rationale for pursuing LRP8 and APOE as potential targets for TNBC  
 In summary, there were 3 major reasons for pursing LRP8 and VLDLR as 
potential therapeutic targets for TNBC. The receptors and ligands are either co-expressed 
or highly overexpressed in human TNBC. The ligands are also found in the breast tumor 
microenvironment and have pathologic roles in hypercholesterolemia and Alzheimer’s 
disease. Single nucleotide polymorphisms are responsible for three major isoforms of 
apolipoprotein E and there is some early indication that ApoE4 carrier status is more 
prevalent in early onset breast cancer. In addition, LRP8 and VLDLR were found to be 
important in the growth and viability of triple-negative breast cancer cell lines, as the 2 
top tier hits from the siRNA screen. 
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2.1. Gene expression profiling 
 To determine global gene expression changes after ApoE4 stimulation, breast 
cancer cell lines were treated with 600 nM of ApoE4. BT-549 and MDA-MB-436 TNBC 
cell lines were treated with 600 nM of ApoE4 using three technical replicates. Total RNA 
was isolated at baseline (0 hours) and at 8 and 48 hours after stimulation from control and 
ApoE4 treated cells, using the animal cell pin protocol from RNeasy Mini kit (Qiagen). 
In brief, breast cancer cells were trysinized and pelleted by centrifugation. Cells were 
lysed and the lysate homogenized using three 30 second pulses in a Sonics Vibra-Cell 
sonicator. Total RNA was then bound to a microcentrifuge RNeasy spin column and 
purified, eluted using RNase-free water, quantified using A260 in a NanoDrop ND1000 
spectrophotometer, and stored at -200C. Gene expression profiling was performed on the 
Affymetrix HG-U133A array, as previously described (3, 12). Unequal variance t-test 
was used to identify differentially expressed genes and FDR was calculated as described 
below.  
 
2.2. Data analysis of gene expression profiles 
 We used two independent data sets to define genes which are overexpressed in 
ER- and HER2-negative cancers. The first data set included Affymetrix U133A gene 
expression data from 294 fine-needle aspiration samples of stage I-III breast cancers 
obtained at MDACC, GSE16716 (n=294, 73 TNBC and 221 non-TNBC cases). This data 
was the discovery set to define candidate TNBC-genes. RNA extraction, hybridization, 
data normalization methods and results from these experiments have been published 
previously (5, 12). The second dataset was comprised of gene expression profiles 
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obtained from frozen tissues of surgically resected breast cancer specimens from 286 
lymph node-negative patients including 56 TNBC and 230 receptor-positive cases, 
GSE2034 (26). This data set was used as a validation set to confirm overexpression of the 
1871 genes. We used unequal variance t-test to compare each probe set between TNBC 
and non-TNBC cases. To account for multiple comparisons, we performed beta uniform 
mixture analysis (BUM) of the p values. This showed a non-uniform distribution and was 
used to calculate false discovery rates (FDR) for particular p-values. Unequal variance t-
test was used to identify differentially expressed genes and false discovery rates (FDR) 
were calculated using the method by Pounds et al. (42, 43). 
In further analysis, we used 2 additional human data sets from the TRANSBIG 
(GSE7390), and Mainz (GSE11121) studies (44, 45). Cell line data sets (51 cell line with 
ArrayExpress accession number E-TABM-157 and 19 cell line data set from M.D. 
Anderson Cancer Center) were also used to determine co-expression of the ApoE – LRP8 
signaling members (46). All gene expression data was generated with Affymetrix gene 
chips, normalized with Affymetrix MAS5.0 algorithm, mean centered to 600, and log 2 
transformed before further analysis.  ER and HER2 status were identified using ESR1 
mRNA expression (probe set 205225_at) and HER-2 mRNA expression (probe set 
16836_s_at), as previously published (47). When one gene had two or more probe sets, 
we retained the probe set with the highest average expression value. We performed the 
class comparison with T-test between ER-positive/HER2-normal and ER-
negative/HER2-normal breast cancer in LRP8 and VLDLR genes.  To adjust for the 
multiple comparisons we calculated False Discovery Rates (FDR) using BRB Array 
tools. The FDR was calculated with the Significance Analysis of Microarrays (SAM) tool 
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as the median number of false positive genes from permutation testing divided by the 
number of nominally significant genes defined from the unperturbed data (44). Statistical 
analyses were performed using the BRB-ArrayTools v 3.8.1 
(http://linus.nci.nih.gov/BRB-ArrayTools.html) and the R software v 2.7.2 (http://www.r-
project.org). All statistical tests were two-sided.  
 
2.3. siRNA screen 
 siRNA screening for each gene was performed in 18 different breast cancer cell 
lines (46). Each of these cell lines were purchased from the ATCC and have been 
previously fully characterized in our laboratory with gene expression profiling and CGH 
analysis. The cell lines included 10 TNBC and 8 receptor-positive cell lines or non-
TNBC. All cell lines were tested for Mycoplasma contamination using MycoAlert Test 
kit (Lonza, Inc.) and growth curves under standard culture conditions were established.  
The methods for the siRNA screen were optimized in the following manner. 3 
different negative controls were used, (i) cells grown in regular OptiMEM media 
(Invitrogen, Inc.), (ii) cells transfected with control siRNA, and (iii) cells grown in 
transfection reagents alone. For siRNA controls, Dharmacon siGENOME-1,-2,-3,-4 and 
Dharmacon ON-TARGETplus siRNA oligonucleotides were tested. PLK1 (polo-like 
kinase 1), KIFF11 (kinesine family member 11), COPB2 (coatomer protein beta2) genes 
and siCONTROL TOX were used as positive controls for gene knockdown and to assess 
transfection efficiency. 96 hours after transfection, viability was determined using 
Promega’s Cell Titer Blue cell viability assay (Madison, WI). Colorimetric measurements 
were performed using a Beckman Coulter Biomek 3000 reader. The optimal transfection 
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conditions were determined for each cell line and included the following considerations, 
(i) best positive and negative siRNA controls as quantified by Z-factor ~1.0 (Z=1-(3 x 
SSD/R) where SSD = sum of standard deivations and R = dynamic range), (ii) the most 
efficient transfection reagent with no viability change in the transfection reagent only 
cells.   
After finding the optimal growth and transfection conditions, the full siRNA 
screen was performed for 674 target genes, each targeted with 4 independent siRNA 
oligonucleotides purchased from Dharmacon, Inc. The original 681 was reduced to 674 
due to the availability of siRNA oligonucleotides. 384-well plates were seeded with 
target siRNAs and the cell line-specific negative and positive control siRNAs with a final 
concentration of 40 nM in 50µl total volume per well in 3 parallel technical replicates. 
Each cell line was added and the plates were incubated at 37oC for 96 hours. The cell 
seeding density that yielded 70-90% confluence in the control wells at 96 hours was used 
for each cell line. Each cell line screen was performed in 3 technical replicates. For every 
10 test plates, a control plate with negative and positive siRNA controls and cells in 
OptiMEM alone was tested. A control plate, including only replicates of positive and 
negative siRNA controls and cells grown in OptiMEM media alone, was inserted every 
10 test plates to assess stability of the assay read out. Cell viability was calculated as 
follows; median value of absorbance in wells containing media alone was subtracted 
from absorbance readings of all other wells, individual readings of each test wells was 
divided by the median value of absorbance corresponding to negative siRNA control 
wells in the same plate and the fraction was multiplied by 100 to derive percent viability. 
Average percent viability across the 3 replicate plates was reported for each siRNA 
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oligonucleotide. Unequal variance t-test was used to assess significant decrease in 
viability compared to control wells. siRNA oligonucleotides for all other experiments 
were from Dharmacon, Inc.  
 
2.4. Bioinformatic analysis to determine top tier hits from siRNA screen 
 The siRNA screen data was regionally normalized to account for differences in 
the dynamic range for the viability results of each cell line. Each cell line was treated 
with 2696 unique siRNAs using three technical replicates per siRNA. Each cell line was 
tested on 9 different test plates with each plate containing 16 negative controls and 8 
positive controls. 
To identify siRNAs that significantly inhibited growth in each cell line, all 
negative control values were pooled for each test plate, the three siRNA technical 
replicates were pooled for each plate, and a one-sided t-test was performed between the 
three siRNA replicates and the pooled negative control values. Beta-uniform mixture 
(BUM) was used to model the p-values of these t-tests and determine threshold cutoff 
values for specific false discovery rates (FDR) (19).  
 To construct a heatmap and siRNA data matrix, the following procedure was 
performed. Shifting of the baseline absorbance status of each plate was accounted for by 
subtracting the values from each well of the regionally normalized data. Therefore, the 
more negative values were identified as evidence of greater growth inhibitory effect and 
more positive values as lower growth inhibitory effect, with the negative controls 
centered at 0 growth inhibitory effect. 
 To identify genes that show significantly differential cell growth inhibition in the 
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group of TNBC cell lines compared to the rest, for each siRNA, we pooled the viability 
values of each siRNA from all 10 TNBC cell lines * 3 replicates. We also pooled the 
viability values of this siRNA from all 8 non-TNBC cell lines * 3 replicates. Two-sided t-
test was used to compare each siRNA in TNBC cell line group to the non-TNBC cell line 
group. BUM and FDR calculations were also performed. The following parameters were 
looked at to compare the inhibitory effect, (i) the magnitude of difference in mean 
inhibition between TNBC cell line group and non-TNBC cell line group and (ii) 
comparison of the number of siRNAs inhibiting the same gene between TNBC cell line 
group and non-TNBC cell line group.  
 To remove inconsistent results, the 61 siRNAs that occurred in the inhibiting 
TNBC group more and inhibiting non-TNBC group were removed from consideration. 
 
2.5. Cell culture conditions 
 Breast cancer cell lines were obtained from the American Type Culture Collection 
(ATCC). The cell lines were cultured in accordance to their recommendations. In 
accordance to ATCC cell line verification recommendations, microscopic examination to 
verify morphology, doubling rate analyses, mycoplasma testing, and short tandem repeat 
(STP) fingerprinting was performed. 
  
2.6. Plasmid rescue experiments 
 To test the specificity of siRNA results, two distinct silent mutations were 
introduced to the siRNA binding regions of an exogenous plasmid of LRP8 (human 
LRP8 pCMV6-AC-GFP) or VLDLR (human VLDLR pCMV6-AC-GFP) to create rescue 
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plasmids of each receptor protein using Agilent Technologies’ QuikChange II XL Site-
Directed Mutagenesis Kit. In brief, mutant strand synthesis was performed by denaturing 
the plasmid DNA templates, annealing mutagenic primers (Sigma-Aldrich, St. Louis, 
MO) with the desired rescue mutation, and primer extension with PfuUltra DNA 
polymerase. Restriction enzyme digestion with Dpn I of the parental strand was 
performed followed by transformation into XL10-Gold ultracompetent cells for 
propagation of the rescue plasmid. The Qiagen Plasmid Maxi kit was used to purify 
rescue plasmids. Breast cancer cell lines expressing either LRP8 or VLDLR were treated 
with siLRP8 or siVLDLR alone or in combination with the siRNA resistant rescue 
plasmid. In combination, the cells were treated with the rescue plasmid for 48 hours 
followed by treatment with the respective siRNA for another 48 and 72 hours. Cell 
viability was assessed at 48 and 72 hours after siRNA transfection using the CellTiter 96_ 
AQueous One Solution Cell Proliferation Assay (Promega).  
 
2.7. Ligand stimulation studies 
 Reelin and apolipoprotein E (ApoE) isoforms 2, 3, and 4 were obtained from 
R&D Systems and MBL International. Both ligands were dissolved in deionized and 
distilled water. Therefore, TNBC cells were serum-starved overnight and grown in 
serum-free media to study the effects of ApoE. In these experiments, controls cells were 
grown in serum-free medium alone. Breast cancer cell lines were treated with 0.030 nM, 
0.060 nM, or 0.120 nM reelin and 150 nM, 300 nM, 600 nM, or 1200 nM of the ApoE 
isoforms for 72 hours. ApoE is found in fetal bovine serum that supplements media. Low 
density lipoprotein receptor-related protein associated protein 1 (LRPAP1 or RAP1, Enzo 
22 
 
Life Sciences), an endogenous inhibitor of LRP8 ligand binding, was added at 200 nM in 
combination with the ApoE isoforms. The CellTiter 96_ AQueous One Solution Cell 
Proliferation Assay (Promega) was used to determine cell proliferation at 24, 48, and 72 
hours. Independent experiments were performed three times for each cell line.  
 
2.8. BrdU incorporation and apoptosis assays 
 Cells were treated with 25 nM siLRP8 or siVLDLR and exposed to 600 or 1200 
nM ApoE4. Bromodeoxyuridine incorporation was measured at 48 and 72 hours using 
the BrdU Cell Proliferation ELISA assay (Roche Applied Science, Indianapolis, IN). 
Caspase-3/7 activity was assayed at 48 and 72 hours after treatment using the Apo-ONE 
Homogeneous Caspase-3/7 Assay (Promega, Madison, WI). Independent experiments 
were performed three times for each cell line.  
 
2.9. LRP8-ApoE4 solid phase ELISA assay 
 Recombinant human LRP8-Histidine tagged (R&D Systems, catalog number 
3520-AR) was bound overnight at 40C to nickel coated 96 well black plates 
(ThermoFisher Scientific, catalog number 15342) at a final concentration of 105 pM in 
PBS on a lateral rocker. In this assay, we tested the effects of RAP and 3 distinct 
commercially available anti-LRP8 antibodies, including LRP8 mouse monoclonal 
antibody targeting amino acids 83-171 (Novus, catalog number H00007804-M01), 
ApoER2/LRP8 polyclonal antibody targeting the C-terminus (Novus, catalog number 
NBP1-96573), and mouse IgG as an isotype control (Abcam, catalog number ab37355). 
RAP was tested at concentrations ranging from 0.01 to 1000 nM and the antibodies were 
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used at final concentrations of 0.01 to 1000 ug/mL. Each antibody was co-incubated with 
600 nM ApoE4 (R&D Systems) for 4 hours at room temperature with the LRP8-coated 
wells. ApoE4-HRP (ApoE4 conjugated to horseradish peroxidase, Novus, catalog 
number NBP1-49529H, 1:2000) was incubated for 1 hour at room temperature.  The 
wells were washed twice with 0.01% PBS with Tween-20 (0.01% PBST). Ligand binding 
was quantified using Thermo Scientific QuantaBlu Fluorogenic Peroxidase Substrate Kits 
(catalog number 15162) at excitation 315-340 nm and emission 370-470 nm. 
 
2.10. mRNA quantitation and qRT-PCR 
 Total mRNA was obtained after siLRP8 and siVLDLR transfection experiments 
with the Qiagen RNeasy kit. Total RNA was reverse transcribed into cDNA and 
quantitative real-time PCR was performed to determine the level of LRP8 and VLDLR 
mRNA knockdown using primers Hs01045922_m1 for VLDLR and Hs00171168_m1 for 
LRP8 (Applied Biosystems).  
 
2.11. Protein quantitation and Western immunoblotting 
 To determine the level of LRP8 and VLDLR protein, total cell lysates were 
collected in RIPA lysis buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail from Calbiochem catalog 
number 539131) and protein was quantified using the BCA Protein Assay (ThermoFisher 
Scientific, Pittsburgh, PA). Western immunoblotting for LRP8 and VLDLR was 
performed using antibodies against LRP8 (H00007804-M01 from Novus, 1:500) and 
VLDLR (NB110-68193 from Novus, 1:1000). The following antibodies and 
24 
 
concentrations were used for reverse phase protein array protein validation: pS473 AKT 
(Cell Signaling, catalog number 9271, 1:1000), AKT (Cell Signaling, catalog number 
9271, 1:1000), pS139 Histone H2AX (Cell Signaling, catalog number 9718, 1:1000), 
Histone H2AX (Cell Signaling, catalog number 2595, 1:1000), pT202 / pY204 ERK1/2 
(Cell Signaling, catalog number 92101L, 1:1000), ERK1/2 (Cell Signaling, catalog 
number 9102, 1:1000), pT180 / p182 p38 (Cell Signaling, catalog number 9211, 1:1000), 
p38 (Cell Signaling, catalog number 9212, 1:1000), COX2 (Epitomics, catalog number 
2169-1, 1:500), Rab25 (Cell Signaling, catalog number 4314, 1:1000), Snail (Cell 
Signaling, catalog number 3895, 1:5000), β-actin (Santa Cruz, catalog number sc-1615, 
1:1000). 
 
2.12. Reverse phase protein array 
To assess the effects of ApoE4 stimulation on oncogenic protein expression and 
determine the phosphorylation status of important regulatory proteins, BT-549 and 
MDA-MB-436 TNBC cell lines were treated with 600 nM of ApoE4 using three 
technical replicates and reverse phase protein array was performed. Total cell lysates 
were isolated at baseline (0 hours) and at 8 and 48 hours after stimulation from control 
and ApoE4 treated cells. In brief, breast cancer cells were trysinized and pelleted by 
centrifugation. Cells were lysed using RIPA lysis buffer. Total protein of the cleared total 
cell lysate was quantified using the BCA Protein Assay. Reverse phase protein array was 
performed as previously described, using 230 antibodies against 201 proteins (48). In 
brief, cellular proteins were denatured with 1% SDS and beta-mercaptoethanol. Serial 
dilution series was prepared in 1% SDS lysis buffer and arrayed onto nitrocellulose-
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coated slides, along with corresponding positive and negative controls. Primary 
antibodies and biotin-conjugated secondary antibodies were used to probe each array. For 
each antibody, the correlation between RPPA signal and Western immunoblotting was 
>0.7. For data analyses, signal intensities were modeled using Supercurve Fitting, log-2 
transformed, and median centered. Unequal variance t-test was used to identify 
differentially expressed proteins and FDR was calculated as described above. 
 
2.13. Metabolomic profiling 
For metabolomic analysis, BT-549 cells were cultured using seven different 
treatment conditions and five technical replicates for each condition. The treatment 
groups are as follows: (i) regular media (T=0 hrs), (ii) regular media (T=48 hours), (iii) 
serum-free media (T=48 hrs), (iv) serum-free media with 600 nM ApoE4 (T=48 hours), 
(v) serum-free media with siCON (T=48 hours), (vi) serum-free media with siLRP8 
(T=48 hours), and (vii) serum-free media with siLRP8/600 nM ApoE4 (T=48 hours). 
After 48 hours, cells were harvested with trypsinization, washed twice with PBS, and 
were stored in liquid nitrogen until shipment to Metabolon, Inc. (Durham, NC) for 
metabolic profiling. Metabolomic profiling was performed using gas 
chromatography/mass spectrometry (GC/MS) and liquid chromatography/tandem mass 
spectrometry (LC/MSMS) methods as described previously (49, 50). 
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2.14. shLRP8 MDA-MB-231 stable knockdown cell line 
 Mission shRNA lentiviral transduction particles against LRP8 were used to 
generate stable knockdown of LRP8 in MDA-MB-231 (Sigma-Aldrich, St. Louis, MO). 5 
shRNA clones (TRCN0000055498, TRCN0000055499, TRCN0000055500, 
TRCN0000055501, TRCN0000055502) were tested to generate the stable knockdown 
cell line. Clones from TRCN0000055498 and TRCN0000055499 batches resulted in the 
most efficient and sustainable LRP8 protein knockdown. Optimal MOI and puromycin 
responses were tested for MDA-MB-231 and optimal conditions were maintained. In 
brief, target cells were transduced with each shLRP8 clone at an MOI of 20 and 
polybrene (Sigma-Aldrich, St. Louis, MO) at final concentration of 8 µg/mL. 48 hours 
after transduction, target cells were selected for with 4 µg/mL puromycin (Sigma-
Aldrich, St. Louis, MO) in DMEM-F12 media (Invitrogen, Grand Island, NY). After 
initial selection, the stable knockdown cell lines were maintained in DMEM-F12 media 
with 2 µg/mL puromycin. Stable knockdown clones were selected using GFP expression 
and level of LRP8 knockdown assessed with Western immunoblotting.  
 
2.15. shLRP8 MDA-MB-231 mouse xenograft studies 
 Female athymic Nude-Foxn1 nude mice (Nu/Nu) were purchased from Harlan 
(Indianapolis, Indiana USA). The mice were housed in laminar flow cabinets under 
specific pathogen-free conditions and used when they were 8 weeks old. The animals 
were maintained in facilities approved by the American Association for Accreditation of 
Laboratory Animal Care in accordance with the current regulations and standards of the 
U.S. Department of Agriculture, Department of Health and Human Services, and 
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National Institutes of Health. For all in vivo experiments, MDA-MB-231 tumor cells 
stably transfected with shRNA against LRP8 in the exponential proliferation phase were 
harvested after brief exposure to a 0.25% trypsin/0.02% EDTA solution. The cell 
suspension was pipetted to obtain single-cell suspensions. The cells were washed, 
resuspended in PBS, and diluted to the desired cell number. Cell viability was determined 
using trypan blue exclusion on an automated ViCELL cell counter. Single-cell 
suspensions of >95% viability were used. In brief, 2 x 106 tumor cells in 0.1 mL of 
RPMI-1640 serum free medium with 50% Matrigel (BD Matrigel, BD Biosciences, San 
Jose, CA, USA) were injected subcutaneously at the 4th pair mammary gland on each 
side. Tumor growth was monitored by palpation and the onset of tumors was noted. 
Tumor size was measured with digital calipers and tumor volume was calculated 
assuming an ellipsoid shape with the following equation: Tumor volume (mm3) = 
(Length x Width2) x π/6. The animals were killed 10 weeks after tumor cell inoculation. 
Afterwards, subcutaneous tumors were harvested and weighed. Individual tumors were 
split for fixation in 4% paraformaldehyde for histology and immunostaining and flash 
frozen in liquid nitrogen for RNA and protein collection. Organs were fixed in Bouin's 
solution for 24 hours to differentiate neoplastic lesions from organ parenchyma. 
Metastases were counted with the aid of a dissecting microscope, and confirmed by 
routine histology. Representative data were obtained from five mice per experimental 
group. 
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2.16. Immunohistochemistry 
 59 ER-negative and ER-positive patient tumor samples were identified for testing. 
In brief, patient data was extracted for all cases, tissue slides were collated, and 
immunohistochemical testing through The University of Texas M.D. Anderson Cancer 
Center Histology Core Laboratory was ordered. The following was the general staining 
protocol performed by the Histology Core. Slides were hydrated with deionized and 
distilled water. Antigen retrieval was performed with citrate buffer. The slides was cooled 
in buffer for 15 minutes and transferred to tris buffered saline (TBS). Slides were blocked 
15 minutes with 3% hydrogen peroxide and rinsed twice with TBS for 5 minutes each 
rinse. Slides were blocked with avidin for 10 minutes and rinsed twice in TBS for five 
minutes each. Slides were blocked with biotin for 10 minutes and rinsed twice in TBS for 
five minutes each. All slides were blocked for 15 minutes with whole serum from the 
animal species corresponding to the secondary antibody  (i.e., if the secondary was anti-
mouse biotinylated then the blocking serum was whole mouse IgG). After blocking, the 
serum was drained off each slide. LRP8 (Abnova PAB4740 – rabbit polyclonal antibody) 
was diluted at 1:50 and VLDLR (Abcam ab 62543 – mouse monoclonal antibody) was 
diluted at 1:50 with TBS buffer for an hour. 
 The association between clinicopathologic variables (age, ER status, HER2 status, 
stage, nuclear grade, and Ki67) and LRP8 protein expression was tested. P-values were 
based on Fisher's exact test with N ≤ 5 (two-sided, 95% confidence interval, α<0.05). 
LRP8 protein expression was divided into discrete variables: (i) LRP8 strong expression, 
LRP8 moderate expression, LRP8 weak expression, or (ii) LRP8 positive, LRP8 
negative. 
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2.17. APOE genotyping of breast cancer patient samples 
 To compare the rate of apolipoprotein E4 (ApoE4) carrier genotype between 
women with ER-negative / ER-positive breast cancer who are <50 years and those who 
are >70 years of age, ApoE genotyping was performed (M. D. Anderson Cancer Center 
Institutional Review Board protocol LAB11-0009). DNA from 50 ER-negative and 50 
ER-positive patients were collected under M. D. Anderson Cancer Center protocol 
LAB03-0479 and used for ApoE genotyping. DNA from late onset breast cancer patients 
(>70 years of age) was collected under M. D. Anderson Cancer Center protocol 2005-
0388 and LAB90-049 and obtained from the M. D. Anderson Cancer Center Breast 
Serum Bank. DNA was quantified using NanoDrop 2000 spectrophotometer and stored at 
-80C until shipment to Kimball Genetics for APOE genotyping through restriction 
fragment length polymorphism analysis. In brief, PCR amplification using primers 
surrounding the APOE gene was performed and followed by restriction digestion 
cleavage of amplified products. Polyacrylamide gels were used to resolve the fragments 
and APOE genotype was determined by band migration patterns.  
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3.1. Identification of 681 overexpressed genes in human triple-negative breast 
cancer 
 In the discovery dataset (n=294), 3,473, 5,413, and 8,418 probe sets were 
differentially expressed in TNBC (n=73) compared to non-TNBC (n=221) at an FDR of 
<0.00001, <0.0001, and <0.001 respectively. Among these probe sets, 1,871, 3,380, and 
5,748 were then overexpressed in TNBC at an FDR of <0.00001, <0.0001, and <0.001 
respectively. Our focus was on the 1871 genes that are overexpressed at an FDR level of 
<0.00001. Sixty-two percent of these genes (n=1162) were also overexpressed in TNBC 
cases (n=56) vs. non-TNBC (n=230) in the second independent validation dataset 
(n=286, individual p-values <0.05). We introduced another filter to reduce the number of 
genes and increase our confidence in these genes by removing all genes with <2.0 fold 
overexpression and with p-values >0.0001 observed in the validation dataset. This 
resulted in 681 genes with at least two-fold overexpression in TNBC with p<0.0001 in 
two independent data sets. The 681 candidate genes belonged to six distinct functional 
categories (Figure 2).  
To increase confidence in these results, we examined what proportion of the 681 
TNBC genes are located in DNA segments that are amplified in TNBC. We used data 
from a subset of 103 cases, including 35 TNBC, from the MDACC discovery set that also 
had matching CGH results from Agilent Human 4x44K CGH arrays. The ADM-2 
algorithm of CGH Analytics v3.4.40 software was used to identify DNA copy number 
anomalies, low level copy number gain was defined as a log2 ratio >0.25. Seventy-three 
TNBC genes (11%) were mapped to DNA segments that showed at least low level copy 
number gain in >10% of TNBC cases.  
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Figure 2. Functional categorization and growth inhibition testing of the 681 
candidate genes identified through analyses of gene expression profiles. Using 
Ingenuity Pathway Analysis, the 681 candidate genes belonged to 6 distinct functional 
families. The inhibition of each gene in a growth assay was tested in a custom siRNA 
screen of 18 breast cancer cell lines. 4 distinct siRNA oligonucleotides against each gene 
were tested in each cell line and the growth inhibitory effect was compared between 
TNBC and non-TNBC cell lines.  
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in individual wells 
GENE1 siRNA #1 
GENE1 siRNA #2 
GENE1 siRNA #3 
GENE1 siRNA #4 
 
 
Incubate 96 hours at 370C 
 
 
Compare significant differences in growth of  
TNBC vs. non-TNBC cell lines 
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3.2. Identification of critical growth genes that sustain the viability of triple-negative 
breast cancer cell lines 
 Each cell line was treated with 4 unique siRNAs against each candidate target in 
384-well plate format. The list of candidate targets was reduced from 681 to 674 due to 
the availability of complete sets of 4 siRNAs for each submitted. Optimized negative and 
positive controls were also included on each plate. The data values were regionally 
normalized to account for multiple standard deviations from the mean. Bioinformatic 
analysis of the results to identify the siRNAs that significantly inhibited cell growth in a 
given cell line was performed by (i) one-sided t-test between the three replicates of each 
siRNA and pooled negative control values and (ii) Beta-uniform mixture (BUM) to 
construct a distribution model of the p-values from the t-tests and establish a threshold 
cutoff value for multiple false discovery rates (FDR) of varying stringency levels. 
 To identify the siRNAs that significantly inhibited cell growth differently between 
the TNBC vs. non-TNBC cell lines, pooled viability values for the three replicates for 
each siRNA from all 10 TNBC cells lines was compared by two-sided t-test to the pooled 
viability values for the three replicates for each siRNA from the 8 non-TNBC cells lines. 
The receptor status according to gene expression distribution is displayed in Appendix 
A1. BUM modeling was performed to establish p-value cutoffs and FDR levels. A list of 
siRNAs that inhibited growth preferentially in the TNBC cell line group was generated 
(Appendix Table A2). A separate list of siRNAs that preferentially inhibited growth in 
the non-TNBC group was also generated (Appendix Table A3). 
  
 
34 
 
3.3. Two high confidence hits, LRP8 and VLDLR, from the siRNA screen 
The number of siRNAs that inhibited growth preferentially out of the set of 4 for 
each gene was compiled from the above comparisons to determine the top tier siRNA hits 
that generated the most reproducible growth inhibition for any one gene. Screen hits were 
categorized by the number of siRNA oligonucleotides which preferentially inhibited 
TNBC cell lines (n=10) compared to non-TNBC cell lines (n=8). There were 27 genes 
which were preferentially inhibited by 2 or more siRNA oligonucleotides in the TNBC 
group. There were 2 genes (LRP8 and VLDLR) which were preferentially inhibited by 3 
of 4 siRNA oligonucleotides in TNBC cell lines and were the highest confidence hits of 
the siRNA screen. They are the low density lipoprotein receptor-related protein 8 (LRP8) 
and the very low density lipoprotein receptor (VLDLR). There were no genes that were 
preferentially inhibited by 4 out of 4 siRNAs in either the TNBC or non-TNBC cell line 
groups.  
 The hits belonged to a variety of functional groups involved in cancer cell 
proliferation and cell cycle regulation. There were also several genes which belonged to 
functional groups that have not been characterized in the context of cancer, including 
several neural signaling components and mediators of metabolism. Initial assessments of 
overall druggability of each candidate targets were performed on the basis of their roles 
in other cancer types, their presence in a successfully targeted gene family, and 
availability of methods and reagents for experimental investigation. 
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3.4. LRP8 and VLDLR, and their ligands, are co-expressed or overexpressed in 
human triple-negative breast cancers 
To investigate the potential role of LRP8 and VLDLR pathway members in 
human TNBC, re-analysis of two other gene expression datasets was performed (55, 56), 
in conjunction with the initial discovery and validation datasets. A major ligand of LRP8 
and VLDLR, reelin, was co-expressed along with the receptors (Table 1). The other 
major ligand, apolipoprotein E (APOE), was highly overexpressed along with LRP8 and 
VLDLR, in 3 of the 4 datasets. The intracellular adapter protein, DAB1, was also co-
expressed at lower levels. The 2 receptors identified from the siRNA screen, LRP8 and 
VLDLR and their ligands APOE and reelin, are co-expressed in human triple-negative 
breast cancer.  
 
3.5. Validation of siRNA screen results through confirmation of target mRNA and 
protein down-regulation 
To confirm that the actual levels of the identified targets, LRP8 and VLDLR, 
were modulated by the siRNAs, transient transfection was performed with the same 
siRNA oligonucleotides used in the siRNA screen. 4 unique siRNAs targeting LRP8 and 
4 unique siRNAs targeting VLDLR were tested separately at 25 and 50 nM. Target 
mRNA levels, protein levels, and viability of 4 different LRP8 and VLDLR-expressing 
TNBC cell lines were measured. mRNA and protein levels decreased after siRNA 
transfection, in the 4 siRNA oligonucleotides (Figure 1 and 2). A dose-dependent 
decrease in the viability of TNBC cell lines was observed compared to a non-targeting 
siRNA control oligonucleotide (Figure 3).  
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Figure 3. Confirmation of siLRP8 and siVLDLR downregulation of target mRNA, 
protein, and growth inhibition. (A) Top panel represents fold mRNA change in LRP8 
after treatment with each of 4 siLRP8 oligonucleotides (denoted siLRP8_1, siLRP8_2, 
siLRP8_3, siLRP8_6). The middle panel represents protein change in LRP8 after each of 
4 siLRP8 in comparison to β−actin. The bottom panel represents fold growth in LRP8 
after siLRP8 treatment in comparison to siCON. (B) Data is shown from siVLDLR 
testing in the same order as panel A. *p<0.001, paired t-test when compared to siCON, 
error bars indicate standard error.  
VLDLR 
β−actin 
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3.6. Validation of siRNA screen results through siRNA-resistant plasmid rescue of 
the phenotype 
To confirm that the siRNA screen hits, LRP8 and VLDLR, were specific and not 
a result of off-target effects, plasmid rescue experiments were performed. siRNA 
resistant plasmids were constructed by introducing silent wobble mutations in the siRNA 
binding region of plasmids encoding for either LRP8 or VLDLR. If the siRNA is unable 
to bind to this siRNA-resistant copy of the gene of interest, the phenotype is rescued. 
This indicates that the loss of phenotype is specific to the target gene knockdown and not 
an artifact of off-target effects. The co-transfection of siRNAs and siRNA-resistant 
plasmid rescued the loss of viability, similar to the measured levels of viability for 
siRNA-resistant plasmid alone and compared to siRNA transfection alone (Figure 4). 
This was observed for each of the 4 siRNAs targeting LRP8 and VLDLR. 
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Figure 4. Plasmid rescue experiments used in validating siRNA screen results. 
Plasmid rescue validation experiments confirmed that growth inhibition was due to 
siRNA-mediated downregulation of LRP8 or VLDLR. TNBC cells were transfected with 
siLRP8 or siVLDLR alone (gray), LRP8 or VLDLR rescue plasmid with silent mutations 
in the siRNA binding region alone (red), or the combination of siLRP8 or siVLDLR and 
rescue plasmid (green). TNBC cell viability was rescued with the combination of siLRP8 
or siVLDLR and rescue plasmid. Representative data from replicate experiments in four 
TNBC cell lines, BT-20, BT-549, MDA-MB-231, and MDA-MB-436.*p<0.01 with 
paired t-test when compared to siRNA alone, error bars indicate standard error. 
 
 
 
 
 
 
 
 
 
 
 
 * 
 *  * 
 * 
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3.7. Functional importance of LRP8-APOE signaling in triple-negative breast 
cancer  
 In order to investigate how LRP8 signaling affects the ability of TNBC tumors to 
proliferate, the combination of in vitro ligand stimulation and loss-of-function studies 
with siRNA and shRNA against LRP8 were completed in LRP8-expressing TNBC cell 
lines. The global gene expression, protein, and metabolic changes that were induced as a 
result of LRP8 signaling were studied using transcriptomic, proteomic, and metabolomics 
arrays. The study ends with investigations into the effect of LRP8 knockdown on TNBC 
tumor xenograft growth, the tissue expression level of LRP8, and the frequency of the 
ApoE4 genotype in early and late onset breast cancer patients. 
 
3.8. Triple-negative breast cancer cell lines express LRP8 and VLDLR and their 
cognate ligands, reelin and APOE  
To validate siRNA screen findings and investigate functional importance of LRP8 
and VLDLR, several breast cancer cell lines were identified from their sensitivity to 
growth inhibition after siLRP8 and siVLDLR in the initial siRNA screen and their level 
of LRP8 and VLDLR mRNA and protein expression. To determine the breast cancer cell 
lines which could serve as model systems for the investigation of LPR8 and VLDLR 
signaling, the target mRNA and protein levels were measured in our panel of 18 breast 
cancer cell lines. We also interrogated a publicly available gene expression dataset of 51 
breast cancer cell lines (46).  
In the breast cancer cell line panel, triple-negative breast cancer cell lines had co-
expression of LPR8, VLDLR, and APOE of mRNA (Table 1). At least 1 non-triple 
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negative breast cancer cell line had high gene expression of APOE with lower expression 
of LRP8 and VLDLR. In the publicly available gene expression dataset of 51 breast 
cancer cell lines, the TNBC cell line group had higher co-expression of LPR8, VLDLR, 
and APOE, compared to the non-TNBC cell line group (Table 1). mRNA and protein co-
expression of the 2 target receptors, LRP8 and VLDLR, was observed for several TNBC 
cell lines (Figure 5 and 6). BT-20, BT-549, MDA-MB-231, and MDA-MB-468 cell lines 
were chosen for validation and functional studies based on co-expression of LRP8 and 
VLDLR, as well as their cognate ligands, Reelin and ApoE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
 
 
 
Figure 5. Co-expression of LRP8/VLDLR receptor - ligand system in breast cancer 
cell line data set. The probe set with the highest mean value and greatest variance was 
selected to compare normalized gene expression values of the two receptors (LRP8 and 
VLDLR), two ligands (APOE and RELN), and major intracellular adaptor protein, 
DAB1. 
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Figure 6. Protein expression of LRP8 and VLDLR in triple-negative breast cancer 
cell lines. Target protein levels in TNBC cell lines were assayed using Western 
immunoblotting. Relative protein levels were normalized to β−actin. 4 TNBC cell lines, 
shown in red, co-express both receptors, LRP8 and VLDLR, and were chosen for further 
validation experiments. 
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Table 1. Class comparison test between ER-negative and ER-positive breast cancer for the LRP8/VLDLR receptor - ligand 
system. 
Number of samples
Data set (ER+HER2-/ER-HER2-) Average SD‡ Average SD‡ Average SD‡ Average SD‡
MDACC/MAQC 133/65 <"0.001 <"0.001 296.8 ± 181.0 558.4 ± 227.4 <"0.001 <"0.001 252.8 ± 176.8 491.8 ± 258.0
Wang 178/56 <"0.001 <"0.001 137.9 ± 108.0 296.8 ± 130.4 <"0.001 <"0.001 250.5 ± 129.6 460.1 ± 277.1
TRANSBIG 124/46 <"0.001 <"0.001 215.6 ± 126.8 421.9 ± 271.0 <"0.001 <"0.001 236.1 ± 129.1 389.6 ± 205.0
Mainz 155/23 <"0.001 <"0.001 110.8 ± 61.2 266.6 ± 122.3 <"0.001 <"0.001 307.0 ± 167.7 636.0 ± 503.6
51 cell line 13/25 0.493 0.638 919.1 ± 401.8 1060.9 ± 784.1 0.135 0.422 439.0 ± 218.4 680.2 ± 1179.1
19 cell line 2/11 0.776 0.166 1069.2 ± 277.0 1145.0 ± 688.2 0.386 0.815 339.1 ± 16.7 469.2 ± 322.5
Number of samples
Data set (ER+HER2-/ER-HER2-) Average SD‡ Average SD‡ Average SD‡ Average SD‡
MDACC/MAQC** 133/65 0.130 0.163 109.9 ± 100.5 133.9 ± 282.7 0.936 0.936 32.0 ± 39.6 31.7 ± 33.0
Wang*** 178/56 0.678 0.689 160.7 ± 125.5 153.9 ± 355.6 0.689 0.689 21.2 ± 16.3 20.4 ± 22.7
TRANSBIG**** 124/46 0.224 0.280 83.4 ± 152.9 68.2 ± 87.8 0.051 0.0846 14.6 ± 15.3 11.9 ± 9.1
Mainz***** 155/23 0.563 0.692 87.3 ± 70.6 78.5 ± 245.3 0.692 0.692 10.0 ± 6.5 7.0 ± 3.5
51 cell line^ 13/25 0.510 0.638 190.3 ± 178.6 229.4 ± 196.3 0.169 0.422 67.3 ± 32.1 53.0 ± 30.8
19 cell line 2/11 0.716 0.815 71.2 ± 149.3 86.7 ± 39.9 0.878 0.815 30.5 ± 24.2 28.7 ± 15.3
Number of samples
Data set (ER+HER2-/ER-HER2-) Average SD‡ Average SD‡
MDACC/MAQC 133/65 <"0.001 <"0.001 1549.0 ± 1363.3 2160.3 ± 2759.1
Wang 178/56 0.034 0.056 1943.8 ± 1110.7 2278.7 ± 2009.1
TRANSBIG 124/46 0.471 0.471 1609.0 ± 711.1 1529.9 ± 666.8
Mainz 155/23 <"0.001 <"0.001 1397.9 ± 629.7 2037.0 ± 1716.3
51 cell line 13/25 0.883 0.883 632.3 ± 1236.2 654.1 ± 1006.8
19 cell line 2/11 0.111 0.279 846.6 ± 1337.9 384.7 ± 226.0
**MDACC/MAQC GSE16716
***Wang GSE2034
****TRANSBIG GSE7390
*****Mainz GSE11121
^ArrayExpress accession number E-TABM-157 
ER+/HER2- ER-/HER2-
FDR†
P-value*
ER+/HER2- ER-/HER2-
FDR†
P-value*
Table 1. Class comparison test between ER+/HER2- and ER-/HER2- breast cancer
ER-/HER2-
LRP8 (Probe set: 208433_s_at) VLDLR (Probe set: 209822_s_at)
FDR†
P-value*
APOE (Probe set: 212884_x_at)
ER+/HER2-
RELN (Probe set: 205923_at) DAB1 (Probe set: 220611_at)
P-value*
ER+/HER2- ER-/HER2-
FDR†
ER+/HER2-
‡SD: Standard Deviation
ER: Estrogen Receptor; HER2: Human Epidermal Growth Factor Receptor 2
ER-/HER2-
*P-value was based on normal distribution. P-values less than .05 were considered statistically significant.
†FDR: False Discovery Rates 
P-value* FDR†
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3.9. Triple-negative breast cancer cell lines express apolipoprotein E isoform 4 
Separate capture ELISA experiments revealed that BT-549 and MDA-MB-436 
express ApoE4 and all other forms of APOE (isoforms 2 and 3 represented by total 
APOE), within the cell and also extruded the lipoproteins into the media, as evidenced by 
binding signals of samples taken from the total cellular lysate and isolated culture 
supernatant (Figure 7). Cells grown in regular media expressed and secreted the highest 
levels of ApoE4 and total ApoE in the media (possibly from non-specific binding of lipids 
from fetal bovine serum in regular media). Cells grown in OptiMem expressed the most 
ApoE4 and total ApoE internally (possibly due to up-regulation of lipid production). 
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ApoE4 and Total ApoE Protein Expression in MDA-MB-436
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Figure 7. ApoE4 and total APOE protein expression in BT-549 and MDA-MB-436 
triple-negative breast cancer cell lines. Detection of ApoE4 and total APOE (ApoE2, 
ApoE3, ApoE4) was performed using ELISA antibody detection. 
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3.10. Reelin stimulates the growth of triple-negative breast cancer cell lines 
Reelin stimulation increases viability of BT-549 and MDA-MB-231 at 96 hours 
after treatment (Figure 8). Reelin stimulation increases viability of MDA-MB-436 at 48 
hours after treatment (Figure 8). The BT-20 cell line was not stimulated by reelin 
treatment (Figure 8). This effect is more pronounced in cell lines which express higher 
levels of both LRP8 and VLDLR protein. Reelin treatment results in lower transient 
stimulation of BT-20 at 48 hours, which expresses higher protein levels of VLDLR. This 
suggests that reelin binds to LRP8 with greater affinity than VLDLR. 
 
 
 
 
Figure 8. Effect on proliferation of reelin treatment on TNBC cell lines. TNBC cell 
lines were treated with 0.03 nM or 0.06 nM reelin for 24, 48, or 96 hours and their relative 
rate of growth assessed with the MTS assay. *p<0.01 with paired t-test when compared to 
untreated control, error bars indicate standard error. 
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3.11. Stimulatory effect of apolipoprotein E is isoform-dependent 
TNBC cell lines were treated with increasing concentrations of human TNBC cell 
lines that co-express LRP8 and VLDLR were treated with reelin and the 3 isoforms of 
ApoE; ApoE2, ApoE3, and ApoE4. ApoE isoform 2 inhibited TNBC cell growth in a 
dose-dependent manner, ApoE isoform 3 did not affect growth, and ApoE isoform 4 
promoted growth of TNBC cell lines (Figure 9). This effect was observed with varying 
lots of recombinant human APOE isoforms from 2 different manufacturers (Figure 9). The 
effects of apolipoprotein E on TNBC viability and growth was isoform dependent, with 
ApoE4 stimulating growth from 2 to 4 fold of mock treated cells. The ligands of LRP8 
and VLDLR, Reelin and ApoE4, stimulated TNBC cells and increased cell viability. 
Transient knockdown of either receptor resulted in the abrogation of the ApoE4-mediated 
stimulatory response, indicating that growth signals were dependent on the interaction 
between ApoE4 and either LRP8 or VLDLR (Figure 10). 
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Figure 9. Differential growth effects of apolipoprotein E isoforms on proliferation of  
TNBC cell lines. BT-20, BT-549, MDA-MB-231, and MDA-MB-436 were treated with 
ApoE2, ApoE3, and ApoE4 isoforms and the effect on proliferation assessed through the 
MTS growth assay. ApoE2 inhibited growth, ApoE3 had an overall null effect on growth, 
and ApoE4 stimulated growth from 1.5 to 6-fold of untreated control. *p<0.01 with paired 
t-test when compared to untreated control, error bars indicate standard error. 
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Figure 10. siLRP8 and siVLDLR abrogates ApoE4 stimulation of TNBC cells. Each of 
siRNAs against LRP8 and VLDLR were applied to TNBC cells alone or with ApoE4.  
siLRP8 or siVLDLR reversed ApoE4 stimulation and reduced growth to that of untreated 
controls. Dark bars indicate ApoE4 or siRNA alone. Lighter colored bars represent the 
combination of siLRP8/ApoE4. *p<0.01 with paired t-test when compared to ApoE4 alone 
and error bars indicate standard error. 
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3.12. LRP8 and VLDLR mediate the stimulatory effect of apolipoprotein E isoform 4 
on TNBC cell lines  
To differentiate between amplified proliferation and reduced apoptosis, TNBC cells 
were treated with 600 and 1200 nM of ApoE4. The level of BrdU incorporation increased 
with increasing ApoE4 concentrations, with no change in caspase-3/7 activity (Figure 11 
and 12). siLRP8 and siVLDLR cell lines were treated with ApoE4, however, there was no 
change in BrdU incorporation or apoptotic activity, indicating the stimulatory effects of 
ApoE4 are mediated through LRP8 and VLDLR.  
 
 
 
Figure 11. Apolipoprotein E isoform 4 stimulation increases the rate of BrdU 
incorporation – process mediated by LRP8. ApoE4 increased BrdU incorporation in 
siCON cells after 48 hours of treatment, increasing in activity from 600 or 1200 nM of 
ApoE4. siLRP8 reduced the level of BrdU incorporation. *p<0.01 with paired t-test when 
compared to siCON alone, error bars indicate standard error. 
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Figure 12. siLRP8 does not affect the level of caspase-3/7 proapoptotic activity. siCON 
(white bars) and siLRP8 (red bars) TNBC cells were treated with 600 or 1200 nM of 
ApoE4. Caspase-3/7 apoptotic activity was measured after 48 hours of treatment. 
 
 
 
 
 
 
 
 
 
54 
 
3.13. Non-triple negative breast cancer cell lines are not stimulated by Reelin or 
apolipoprotein E isoform 4 
To investigate if the differential stimulation effects of the 3 different ApoE isoforms 
were unique to TNBC cells, receptor-positive cell lines were treated with the 500 nM of 
each APOE isoform. BT-474 (ER+/HER2+), MCF-7 (ER+/HER2-), and SK-BR-3 (ER-
/HER2+) were treated and their viability was not affected by the APOE isoforms (Figure 
13). 
 
 
Figure 13. Apolipoprotein E isoform 4 has no significant effect on proliferation of non-
TNBC cell lines. Non-TNBC cell lines with varying receptor status were treated with the 
three ApoE isoforms at 600 nM. There were no significant differences in growth from 
untreated controls when testing in regular or serum-starved media, with the exception of 
SK-BR-3. 
* 
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     Control                    ApoE4 600 nM      ApoE4 1200 nM 
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3.14. ApoE4 stimulation results in cell cycle progression of triple-negative breast 
cancer cell lines 
Two doses of ApoE4 were given and FACS analysis was performed to ascertain the 
potential changes in cell cycle distribution given the growth stimulatory properties of 
ApoE4. BT-20 and BT-549 were pushed into the synthesis phase, while MDA-MB-231 and 
MDA-MB-436 were pushed into the G2/M phase (Figure 14). BT-20 and BT-549 cell lines 
had an S phase increase, for BT-20 18% in mock treated control cells to 24% in 600 nM 
ApoE4 and 30% in 1500 nM ApoE4. For MDA-MB-231 and MDA-MB-436 cells, the 
G2/M fraction increased with ApoE4 treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Apolipoprotein E isoform 4 stimulation mediates S- and G2/M-phase cell 
cycle progression in TNBC cells. BT-20 and BT-549 cell lines shifted from G1 to S phase, 
while the G2/M fraction increased in MDA-MB-231 and MDA-MB-436 cells. *p<0.05 with 
paired t-test when compared to untreated controls, error bars indicate standard error. 
BT-20 
 
 
 
 
BT-549 
 
 
 
 
MDA-MB-231 
 
 
 
MDA-MB-436 
56 
 
3.15. Inhibition of apolipoprotein E binding abolishes the growth stimulatory effect on 
triple-negative breast cancer cell lines 
To test whether the stimulatory effect on viability was a result of ApoE binding to 
LRP8/VLDLR, LRP8 and VLDLR expressing breast cancer cell lines were treated with 
ApoE4 alone or the combination of ApoE4 and RAP1, an endogenous inhibitor of ApoE 
binding to LRP8/VLDLR. The addition of RAP1 abolished the stimulatory effect previously 
observed at 72 hours (Figure 15).  
 To test whether commercial antibodies that target different regions of LRP8 can 
inhibit binding of ApoE4 to its cognate receptor, LRP8. Previously, treatment of LRP8-
expressing breast cancer cell lines with the ApoE4 isoform resulted in greater cell viability 
(MTS assay – reduction of NADPH produced in cell culture, measure of metabolic activity). 
The objective of this experiment was to (i) develop a custom, solid phase binding assay for 
LRP8 and ApoE4, (ii) identify commercial antibodies that may inhibit the binding 
interaction between LRP8 and ApoE4, and (iii) identify potential binding domains on LRP8 
which may be targeted. A mouse monoclonal antibody against LRP8 reduced the binding 
affinity of recombinant human LRP8 and ApoE4 using an ELISA binding assay (Figure 16). 
In comparison, a mouse polyclonal antibody against the intracellular C-terminal region of 
LRP8 and mouse IgG antibody did not affect the binding of recombinant LRP8 and ApoE4 
(Figure 16).  
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*representative data, 2 expts (48hrs) 
ApoE4 stimulation of TNBC cells is 
inhibited by RAP (an inhibitor of ApoE binding) 
ApoE4 alone 
 
ApoE4 and RAP 200 nM 
 
 
 
Figure 15. RAP1-induced abolishes proliferative effect of ApoE4 on TNBC cell lines. 
RAP treatment (black lines) abolished the ApoE4 stimulatory effect (red lines) when 200 
nM of RAP was combined with greater than 150 nM of ApoE4 after 48 hours of 
treatment. *p<0.001 with paired t-test when compared to ApoE4 alone, error bars 
indicate standard error. 
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Figure 16. LRP8 monoclonal antibody abrogates binding between LRP8 and 
ApoE4. In an ELISA solid-phase binding assay, RAP and a monoclonal antibody 
targeting the ApoE4 binding region of LRP8 reduced the binding activity level between 
recombinant human LRP8 and ApoE4. *p<0.05 with paired t-test when compared to 
mouse IgG alone, error bars indicate standard error.  
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3.16. ApoE4 stimulation rescues TNBC cells from serum-starvation effects by down-
regulating members of lipid biosynthesis 
To investigate the mechanisms controlling the robust growth effect after ApoE4 
stimulation, transcriptional, proteomic, and metabolic profiling was performed using the 
same experimental schema described in the Methods section.  Global profiling was 
performed in the BT-549 and MDA-MB-436 cell lines, which had the most consistent 
proliferative effects in response to ApoE4 stimulation as well as higher expression of 
LRP8 and VLDLR according to Western blotting. During serum starvation, most of the 
gene expression changes occurred between 8 and 48 hours of treatment, with the highest 
number of common probe sets occurring during the entire 48 hour treatment period 
(Table 2, Control T00 vs. T48). Likewise, ApoE4-induced gene expression changes were 
concentrated at the 48 time point, indicating that gene expression changes after 8 hours of 
treatment are responsible for the transcriptional changes related to serum starvation and 
ApoE4 stimulation. Each set of triplicate clustered together with a second level of 
separation occurring between the group of T0/T8 and the group at T48, with this effect 
being more obvious with BT-549 than MDA-MB-436 (Figure 17). For these reasons, 
further analyses focused on the 48 hour time point comparisons. 
 Serum-starvation induced the upregulation of steroid biosynthesis and lipid and 
amino acid metabolism pathways, while downregulating pathways associated with 
mitotic division and nucleotide metabolism (Figure 18). The lipid biosynthesis network 
connecting the  upregulated starvation-induced genes centered around SREBF2 (Figure 
19). ApoE4 stimulation increased expression of genes associated with chemokine 
signaling, while downregulating members of steroid biosynthesis pathways (Figure 19). 
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This dampening or normalization of starvation-induced steroid biosynthesis rescues 
TNBC cells from starvation by supplying them with an exogenous energy source 
mediated by ApoE4.  
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Table 2. Global profiling changes after serum-starvation and ApoE4 treatment in 
TNBC cell lines 
Serum-starvation regulated genes  BT-549 MDA-MB-436 
Common 
probe sets 
Control T00 vs. T08 Threshold p<0.005 p<0.005  
 Up 226 219 4 
 Down 304 295 64 
     
Control T08 vs. T48 Threshold FDR 0.01 p<0.005  
 Up 427 362 94 
 Down 405 225 50 
     
Control T00 vs. T48 Threshold FDR 0.01 p<0.005  
 Up 696 315 108 
 Down 663 201 67 
     
ApoE4 regulated genes 
 
BT-549 MDA-MB-436 
Common 
probe sets 
Treated vs. Control (T08) Threshold FDR 0.05 p<0.005  
 Up 167 132 7 
 Down 123 114 1 
     
Treated vs. Control (T48) Threshold FDR 0.05 p<0.005  
 
Up 638 
 
113 16 
 
 
Down 589 167 38 
 
Common to BT-549 and MDA-MB-436 
Serum-starvation genes 
Control T00 vs. T48 
ApoE4 genes 
Treated vs. Control (T48) 
Up-regulated Down-regulated Up-regulated Down-regulated 
ABCD4 
ACAT2 
ANK2 
ANXA4 
AP1M2 
ARG2 
ASNS 
BNIP3L 
BST2 
C14orf1 
C6orf62 
CAPRIN2 
CAST 
ABCF2 
ACP1 
ARD1A 
BCLAF1 
BOP1 
C8orf33 
CCDC56 
CCND1 
CTPS 
CYP1B1 
DDX18 
DNAJC9 
EIF2B3 
CAV2 
CTSB 
CXCL2 
CXCL3 
CYR61 
FOSL1 
GPX1 
KPNB1 
NEDD4L 
PLAU 
SEPW1 
TBL1X 
TGFBI 
 
 
ACAT2 
ACLY 
AP1M2 
C14orf1 
CYP51A1 
DBI 
DHCR24 
DHCR7 
EBP 
FADS1 
FASN 
FDFT1 
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CCNG1 
CEP170 
CHP 
CYP51A1 
DCAF6 
DDIT4 
DHCR7 
DZIP1 
EBP 
EGFR 
FADS1 
FADS2 
FASN 
FDFT1 
FDPS 
FTL 
G6PD 
GARS 
GGPS1 
HERC5 
HEXB 
HMGCR 
HMGCS1 
HSD17B7 
HSP90B1 
IDH1 
IDI1 
IFI44 
IFI6 
IFIH1 
IFIT1 
IFIT3 
INSIG1 
ISG15 
ISG20 
ITGB5 
JUND 
KIAA0430 
LAMB2 
LDLR 
LPIN1 
MAGED1 
NNT 
NPC1 
NPC2 
NSDHL 
OAS1 
PHGDH 
PMAIP1 
PNMA2 
EMG1 
FHL2 
FOSL1 
GLRX3 
GYG1 
HSP90AB1 
HSPD1 
IMPDH2 
KPNB1 
LSG1 
MCM7 
MRPS33 
MT1X 
MT2A 
NME1 
NOL7 
NOLC1 
PFAS 
PLAU 
POP4 
PPIF 
PPIH 
PRPF4 
PSMD3 
PUF60 
RANBP1 
RANGAP1 
RFTN1 
RRM2 
RRP9 
SEPW1 
SERPINE1 
SRM 
SRRT 
TH1L 
TOMM70A 
TPM1 
VDAC3 
 
FDPS 
HMGCS1 
HSD17B12 
HSD17B7 
IDI1 
INSIG1 
LDLR 
LIPA 
LPIN1 
LSS 
MICA 
NEU1 
NPC2 
NSDHL 
S100A10 
SC4MOL 
SCD 
SLC25A1 
SQLE 
TMEM97 
TUBA1A 
ZC3HAV1 
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POFUT2 
RHOQ 
RSAD2 
SC4MOL 
SCD 
SLC2A3 
SLC38A2 
SQLE 
SREBF2 
STX16 
TCF7L2 
TMX1 
TPBG 
TPD52L1 
TRADD 
TRIB3 
TTC3 
TUBA1A 
WARS 
WSB1 
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Figure 17. Global profiling changes in BT-549 and MDA-MB-436 cell lines shows 
modulation of lipid biosynthesis during serum-starvation and after ApoE4 
treatment. Untreated control and ApoE4 treated cells were assayed at baseline, 8 hours, 
and 48 hours of treatment in triplicate (T00 Control, T08 Control, T48 Control, T48 
ApoE4, T48 ApoE4). A heatmap of hierachical clustering of the samples is shown, using 
top 20% variable probe sets (probe sets = 4457), measured by median absolute deviation, 
and using Pearson distance and Ward linkage.  
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Figure 18. Significantly differentially regulated canonical pathways of TNBC cells at baseline and with 48 hours of serum-
starvation vs. ApoE4 treatment. Serum-starvation and ApoE4 regulated genes that were common to both BT-549 and MDA-MB-
436 were imputed into Ingenuity Pathway Analysis for canonical pathway analysis and the results are as depicted (Table 3). At time 
point 48, serum-starvation induced the upregulation of pathways involved in steroid biosynthesis and lipid metabolism. ApoE4 
treatment rescued this starvation-induced effect and reduced the activation of steroid biosynthesis pathways. 
 Upregulated pathways after serum-starvation                                       Downregulated pathways after ApoE4 stimulation 
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Figure 19. Major regulated transcriptional networks in TNBC cells with 48 hours of serum-starvation vs. ApoE4 treatment. 
The serum-starvation regulated genes belong to an interacting network centered on the transcriptional regulator, SREBF2. ApoE4 
treatment rescues TNBC cells from starvation conditions by downregulating interacting steroid biosynthesis factors, which are 
responsible for growth and survival during serum-starvation conditions.
           Upregulated network after serum-starvation                                Downregulated network after ApoE4 stimulation 
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3.17. MAPK signaling mediates ApoE4 downstream signaling for TNBC cell 
proliferation To determine the protein mediators of proliferation after ApoE4 
stimulation, reverse phase protein array was performed after 48 hours of ApoE4 
treatment in BT-549 and MDA-MB-436. Consistent protein changes occurred at time 
point 48, consistent with the results from gene expression profiling (Figure 20). Ingenuity 
Pathway Analysis showed that the activated proteins were interconnected through the 
MAPK signaling network (Figure 21, Table 3). Proteins repressed after ApoE4 treatment 
were involved in ribosomal assembly and protein translation (Figure 21, Table 3).  
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Table 3. Perturbation of oncogenic protein expression after ApoE4 treatment 
Serum-starvation regulated proteins BT-549 MDA-MB-436 Common 
 
Control T00 vs T08 Threshold FDR 0.05 FDR 0.05  
 Up 60 14 3 
  Down 31 16 8 
     
Control T08 vs T48 Threshold FDR 0.05 FDR 0.05  
 Up 21 67 17 
  Down 25 62 16 
     
Control T00 vs T48 Threshold FDR 0.05 FDR 0.05  
  Up 66 31 24 
  Down 45 34 20 
     
     ApoE4 regulated proteins BT-549 MDA-MB-436 Common 
Treated vs Control (T08) Threshold p<0.05 p<0.05  
  Up 13 18 5 
  Down 12 10 1 
     
Treated vs Control (T48) Threshold FDR 0.05 FDR 0.05  
  Up 59 51 12 
  Down 53 36 12 
     
 
ApoE4 upregulated proteins (n=5) 
Treated vs Control (T08) 
 
ApoE4 upregulated proteins (n=12) 
Treated vs Control (T48) 
HIF1a 
p53 
PKC-alpha_pS657 
Snail 
VEGF 
 
Caspase-7_cleavedD198 
CDKN1B 
ERRFI1 
HIF1a 
HistoneH2AX_pS139 
MAP2K1 
MAPK14_pT180/182 
p53 
PTGS2 
PTK2 
Rab25 
Snail 
 
ApoE4 downregulated proteins (n=1) 
Treated vs Control (T08) 
 
ApoE4 downregulated proteins (n=12) 
Treated vs Control (T48) 
AMPK_pT172 
 
AR 
Chk2_pT68 
C-Raf_pS388 
CyclinD1 
EGFR 
EIF4EBP1_pS65/T70 
HER2 
RPS6_pS235/236/240/244 
RPS6KB1 (p70S6K_pT389) 
SPARC 
Stat3_pY705 
YAP 
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Figure 20. RPPA heatmap of hierarchical clustering of control and ApoE4 treated experimental samples using samples 
arranged in order (n=230 antibodies, clustering performed using Pearson distance and median centered). A heatmap depicting 
samples arranged in order (rows) is shown with antibodies (columns) listed in the top row (median centered array). Yellow boxes 
highlight antibody signals which changed significantly between the control and ApoE4 treated samples at 48 hours. 
-3.017 5.171 
(Log 2) 
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Figure 21. Major regulated protein networks in TNBC cells with 48 hours of serum-starvation vs. ApoE4. Proteins from Table 4 
were imputed into Ingenuity Pathways Analysis for canonical pathway and molecular network analyses and the results are as shown. 
ApoE4 activated proteins are involved in the transmittal of exogenous growth signals through cytoplasmic MAPK signaling to further 
activate transcriptional regulators such as p53 and CDKN1B. ApoE4 represses proteins involved in protein translation.
      Upregulated proteins after ApoE4 stimulation                            Downregulated proteins after ApoE4 stimulation 
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To confirm the RPPA array findings, Western immunoblotting of the ApoE4 
activated proteins was performed (Figure 22). Transient and stably transfected LRP8 
knockdown cell lines were established to test if ApoE4 stimulation affects TNBC cells 
with lower levels of ApoE’s cognate receptor. The MDA-MB-231 shLRP8 stable 
knockdown cell line was used to establish the nude mice xenografts. LRP8 knockdown 
efficiency was similar in both BT-549 and MDA-MB-231 LRP8 knockdown cell lines. In 
BT-549 parental cells, ApoE4 increased the protein levels of phosphorylated serine-473 
of histone H2AX, COX2, Rab25, and Snail. In BT-549 siLRP8 cells, this increase was 
reduced for phosphorylated serine-473 of histone H2AX. In BT-549 siCON and siLRP8 
cells, there were no detectable levels of COX2, Rab25, or Snail. In MDA-MB-231 
parental cells, there were minimal increases in phosphorylated serine-473 of histone 
H2AX and Snail after ApoE4 treatment. In MDA-MB-231 shLRP8 cells, both proteins 
were slightly reduced in comparison to shCON. 
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Figure 22. Western immunoblotting validation of RPPA results. Western blot confirmation 
of key activated proteins is depicted. BT-549 and MDA-MB-231 cell lines were treated with 600 
nM ApoE4 for 48 hours. BT-549 cells transiently transfected with siLRP8 and a stably 
transfected shLRP8 MDA-MB-231 cell line were treated concurrently. The increased protein 
levels of phosphorylated histone H2AX (S139), COX2, RAB25, and SNAIL were confirmed for 
BT-549. The results for MDA-MB-231 were less consistent with the RPPA results. 
73 
 
3.18. Metabolomic profiling indicates that TNBC cells use alternative metabolic 
pathways during serum starvation and coordinate LRP8-ApoE4 signaling to rescue 
cells from cellular stress  
BT-549 cells were treated with ApoE4 for 48 hours and GC/MS and LC/MS/MS 
profiling platforms were used by Metabolon, Inc. to determine the metabolic biochemical 
changes that mediate growth and survival of ApoE4 activated cells. Three comparisons 
were focused upon, the effects of serum-starvation (serum-free cells at 48 hours / regular 
media cells at 48 hours), the rescue effects of ApoE4 treatment (ApoE4 treated cells at 48 
hours / serum-free cells at 48 hours), and the rescue effects potentially reversed by LRP8 
knockdown (siLRP8+ApoE4 at 48 hours / siCON at 48 hours). Serum-starvation resulted 
in the activation of Warburg metabolism, with increased tryptophan and reduced NAD+ 
levels (Table 4). Glycolysis intermediates, such as fructose-6-phosphate and 3-
phosphoglycerate, were increased in serum-starved cells. Reduced glutathione and 
hydroxycholesterol metabolites generated by reactive oxygen species were also elevated 
(Figure 23 and 24). 
 In response to ApoE4 treatment, the cells had decreased levels of the previously 
activated glycolysis intermediates and reduced levels of some oxidative stress chemicals 
and cholesterol metabolites (Figure 24).  In response to LRP8 knockdown, cells reversed 
some of the rescue effects and reconstituted levels of key chemicals in nucleic acid 
metabolism and lipid metabolites and re-entered the pentose phosphate pathway to 
produce nucleotide precursors and intermediates (Figure 25). 
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Table 4. 192 of 273 changing metabolites in BT-549 and MDA-MB-436 in response 
to serum-starvation and ApoE4/siLRP8 treatment 
 
Super 
Pathway Sub Pathway 
Biochemical 
Name KEGG 
SF-48 / 
REG-48 
APO-48 / 
SF-48 
LRP-48 / 
CTRL-48 
A/L-48 / 
CTRL-48 
Amino acid 
Glycine, serine, 
threonin metabolism 
serine C00065 1.15 1.28 1.24 1.5 
threonine C00188 1.13 1.33 1.18 1.54 
N-
acetylthreonine C01118 1.01 1.29 1.25 1.28 
Alanine and aspartate 
metabolism 
aspartate C00049 0.82 0.81 0.92 1.03 
asparagine C00152 1.92 1.14 1.26 1.29 
beta-alanine C00099 0.37 1.25 1.13 1.1 
N-acetylalanine C02847 1.2 0.99 0.95 0.91 
Glutamate 
metabolism 
glutamine C00064 3.36 1.33 2.09 2.11 
pyroglutamine* 
  
1.84 1.05 1.11 1.1 
gamma-
aminobutyrate 
(GABA) 
C00334 0.19 1.31 1.18 1.55 
N-
acetylglutamate C00624 1.85 0.72 1.04 0.77 
N-acetyl-
aspartyl-
glutamate 
(NAAG) 
C12270 1.3 1 0.99 0.9 
Histidine metabolism 
histidine C00135 1 1.1 1.28 1.46 
imidazole 
propionate   0.38 0.89 0.98 1.3 
Lysine metabolism 
lysine C00047 1.13 1.35 1.32 1.63 
2-aminoadipate C00956 0.21 0.68 1 0.68 
Phenylalanine & 
tyrosine metabolism 
phenylalanine C00079 1.13 1.34 1.19 1.42 
tyrosine C00082 1.18 1.35 1.18 1.5 
3-(4-
hydroxyphenyl)la
ctate 
C03672 2.41 1.06 1.18 1.05 
phenylacetylglyci
ne C05598 
1.23 0.57 0.84 0.74 
Tryptophan 
metabolism 
kynurenine C00328 0.43 1.03 1.12 1.21 
tryptophan C00078 25.51 1.64 1.25 1.55 
Valine, leucine and 
isoleucine metabolism 
isoleucine C00407 1.13 1.26 1.17 1.3 
leucine C00123 1.11 1.31 1.23 1.41 
valine C00183 1.2 1.3 1.2 1.38 
isobutyrylcarnitin
e   
0.69 1 1 1 
2-
methylbutyrylcar
nitine (C5) 
  
0.07 1.3 0.87 0.68 
isovalerylcarnitin
e   
0.08 1 1 1 
Cysteine, methionine, 
SAM, taurine 
metabolism 
cystathionine C02291 1.62 1.16 1.18 1.18 
methionine 
sulfoxide C02989 2.19 0.69 1.11 0.85 
hypotaurine C00519 0.26 1.33 1.14 1.24 
S-
adenosylhomocy
steine (SAH) 
C00021 1.07 0.87 1.09 1.1 
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methionine C00073 1.23 1.32 1.19 1.41 
N-
acetylmethionine C02712 1.55 1.16 1.13 1.31 
homocysteine C00155 1.45 0.83 1.31 1.12 
Urea cycle; arginine-, 
proline-, metabolism 
dimethylarginine 
(SDMA + ADMA) C03626 2.12 1.39 1.19 1.79 
arginine C00062 1.4 1.34 1.39 1.69 
N-acetylornithine C00437 0.66 1.07 0.97 1.05 
trans-4-
hydroxyproline C01157 0.45 0.82 1.34 1.26 
argininosuccinat
e C03406 
0.69 1.65 0.86 1.3 
Creatine metabolism 
creatine C00300 0.53 1.03 1.1 1.11 
creatinine C00791 0.45 1.35 1.1 1.04 
Polyamine 
metabolism 
putrescine C00134 0.34 0.67 0.41 0.42 
spermidine C00315 1.27 0.9 0.95 0.88 
spermine C00750 1.58 2.34 0.67 0.99 
Glutathione 
metabolism 
glutathione, 
reduced (GSH) C00051 1.21 1.08 0.93 0.95 
5-oxoproline C01879 1.66 1.09 1.16 1.3 
S-
lactoylglutathion
e 
C03451 1.78 0.31 1.99 0.48 
Peptide 
Dipeptide 
glycylglycine C02037 1.35 1.11 1.3 1.42 
glycylproline 
  
1.4 1.67 1 1.36 
pro-hydroxy-pro 
  
0.35 1.64 1.21 1.47 
phenylalanylglut
amate   1.25 1.4 1.18 1.32 
cysteinylglycine C01419 1.38 0.94 1.03 1.08 
isoleucylglycine 
  
1.71 1.08 1.05 0.84 
isoleucylserine 
  
3.14 1.29 0.77 0.97 
leucylglycine 
  
2.2 1.26 1.11 1.23 
prolylglutamate 
  
1.36 1.13 1.04 1.32 
gamma-glutamyl 
gamma-
glutamylvaline   1.72 1.17 1.01 1.03 
gamma-
glutamylleucine   1.34 1.1 1.12 1.11 
gamma-
glutamylglutamat
e 
  
1.43 0.96 0.81 0.85 
gamma-
glutamylphenylal
anine 
  
1.47 1.04 1.27 1.2 
Carbo-
hydrate 
Aminosugars 
metabolism erythronate*   1.21 0.9 1.01 0.93 
Fructose, mannose, 
galatose, starch, 
sucrose 
lactose C00243 1.33 0.94 1.2 1.17 
6'-sialyllactose G00265 1.17 0.84 1.07 0.95 
mannitol C00392 0.45 0.84 1.27 1.95 
Glycolysis, 
gluconeogenesis, 
pyruvate metabolism 
glucose 1-
phosphate C00103 0.81 0.66 0.97 0.79 
Isobar: fructose 
1,6-diphosphate, 
glucose 1,6-
diphosphate, 
myo-inositol 1,4 
  
2.35 0.16 1.82 0.4 
3-
phosphoglycerat C00597 1.84 0.5 0.92 0.73 
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e 
dihydroxyaceton
e phosphate 
(DHAP) 
C00111 1.69 0.33 1.46 0.48 
pyruvate C00022 2.16 0.71 1.1 0.81 
lactate C00186 1.18 0.95 1.09 1.03 
Nucleotide sugars, 
pentose metabolism 
6-
phosphogluconat
e 
C00345 0.76 1.05 1.04 1.03 
sedoheptulose-
7-phosphate C05382 0.7 1.21 1.2 2.19 
ribose C00121 1.79 0.52 1.43 1.26 
ribose 5-
phosphate C00117 1.17 0.52 1.6 1.25 
Isobar: ribulose 
5-phosphate, 
xylulose 5-
phosphate 
  
1.2 0.54 1.89 1.49 
UDP-glucose C00029 1.18 0.75 1.05 0.79 
UDP-
glucuronate C00167 0.95 0.92 0.82 0.69 
xylitol C00379 2.63 0.52 1.48 1.52 
xylonate C05411 1.81 0.9 0.96 0.94 
  Krebs cycle 
succinate C00042 1.68 0.77 1 0.91 
fumarate C00122 1.94 0.96 1.04 1.25 
malate C00149 0.94 0.83 0.98 0.88 
Lipid 
Essential fatty acid 
linoleate 
(18:2n6) C01595 0.54 1.17 1.16 1.34 
linolenate [alpha 
or gamma; 
(18:3n3 or 6)] 
C06427 0.39 1.04 0.92 0.97 
dihomo-
linolenate 
(20:3n3 or n6) 
C03242 0.23 1.14 1.6 2.1 
eicosapentaenoa
te (EPA; 20:5n3) C06428 0.53 1.06 1.14 1.08 
docosapentaeno
ate (n3 DPA; 
22:5n3) 
C16513 0.35 1.09 1.63 1.8 
docosapentaeno
ate (n6 DPA; 
22:5n6) 
C16513 0.22 1.36 1.68 2.59 
docosahexaenoa
te (DHA; 22:6n3) C06429 0.26 1.29 1.42 2.02 
Medium chain fatty 
acid 
heptanoate (7:0) C17714 1.27 1.23 0.83 0.99 
caprylate (8:0) C06423 1.36 0.9 1.15 1.25 
laurate (12:0) C02679 1.32 1.07 1.15 1.11 
Long chain fatty acid 
myristate (14:0) C06424 1.1 1.15 1.07 1.09 
myristoleate 
(14:1n5) C08322 1.4 1.17 1.03 1.06 
10-
heptadecenoate 
(17:1n7) 
  
0.48 2.2 1.29 3.16 
oleate (18:1n9) C00712 0.85 1.15 1.29 1.67 
10-
nonadecenoate 
(19:1n9) 
  
0.55 3.18 1.3 5.14 
eicosenoate 
(20:1n9 or 11)   0.97 1.03 1.21 1.41 
dihomo-linoleate C16525 0.57 1.05 1.34 1.72 
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(20:2n6) 
mead acid 
(20:3n9)   0.42 0.94 1.03 1.21 
arachidonate 
(20:4n6) C00219 0.16 1.3 1.69 2.43 
docosadienoate 
(22:2n6) C16533 0.86 0.87 1.15 1.11 
  
2-
hydroxystearate C03045 3.11 0.57 1.02 0.76 
2-
hydroxypalmitate   3.94 0.51 0.98 0.67 
Fatty acid, 
dicarboxylate 
2-
hydroxyglutarate C02630 1.66 0.71 0.87 0.58 
Fatty acid, amide stearamide C13846 0.61 2.04 1.53 1.55 
Endocannabinoid 
oleic 
ethanolamide   1.33 1.27 1.24 1.9 
palmitoyl 
ethanolamide   1.29 1.22 1.2 1.49 
Fatty acid metabolism 
(also BCAA 
metabolism) 
propionylcarnitin
e C03017 
0.12 0.76 0.63 0.39 
butyrylcarnitine 
  
0.17 1.22 1.72 1.51 
Carnitine metabolism 
deoxycarnitine C01181 0.51 1.06 1.06 1.07 
carnitine C00318 0.1 1.26 1.29 1.2 
3-
dehydrocarnitine
* 
  
0.31 1 1 1 
acetylcarnitine C02571 0.16 1.19 1.28 1.01 
Glycerolipid 
metabolism 
choline 
phosphate C00588 4.21 0.67 1.32 0.92 
ethanolamine C00189 0.96 1.37 1.19 2.51 
phosphoethanol
amine C00346 0.49 1 1.84 1.83 
choline C00114 1.02 1.23 1.32 1.65 
glycerophosphor
ylcholine (GPC) C00670 1.59 0.74 1.15 0.57 
cytidine 5'-
diphosphocholin
e 
C00307 1.13 0.7 0.95 0.75 
Lipid 
Inositol metabolism scyllo-inositol C06153 0.19 0.94 0.8 0.86 
Ketone bodies 
3-
hydroxybutyrate 
(BHBA) 
C01089 1.15 1.07 1.31 1.27 
Lysolipid 
1-
palmitoylglycero
phosphoethanol
amine 
  
1.55 1 1.07 1.19 
2-
palmitoylglycero
phosphoethanol
amine* 
  
0.89 1.26 1.61 1.57 
2-
palmitoleoylglyce
rophosphoethan
olamine* 
  
1.48 1.04 1.26 1.03 
1-
stearoylglycerop
hosphoethanola
mine 
  
1.5 0.64 1.28 0.95 
1-
oleoylglyceropho
sphoethanolamin
e 
  
1.3 0.8 1.1 0.96 
2-
linoleoylglycerop   1.07 1.02 1.42 1.09 
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hosphoethanola
mine* 
2-
arachidonoylglyc
erophosphoetha
nolamine* 
  
0.92 1.11 1.33 1.06 
2-
docosapentaeno
ylglycerophosph
oethanolamine* 
  
0.66 1.2 1.38 0.97 
2-
docosahexaenoy
lglycerophospho
ethanolamine* 
  
0.74 1.18 1.31 1.1 
2-
myristoylglycero
phosphocholine* 
  
0.79 1.29 1.4 1.24 
2-
palmitoylglycero
phosphocholine* 
  
0.72 1.11 1.51 1.01 
1-
linoleoylglycerop
hosphocholine 
C04100 0.49 1.04 1.42 0.85 
2-
linoleoylglycerop
hosphocholine* 
  
0.53 1.05 1.47 0.87 
2-
arachidonoylglyc
erophosphocholi
ne* 
  
0.41 1.04 1.43 0.96 
1-
docosapentaeno
ylglycerophosph
ocholine* 
  
0.36 1.03 1.07 0.71 
2-
docosapentaeno
ylglycerophosph
ocholine* 
  
0.27 1.31 1.64 1.27 
2-
docosahexaenoy
lglycerophospho
choline* 
  
0.3 1.05 1.38 1.12 
1-
stearoylglycerop
hosphoinositol 
  
0.66 1.18 1.2 0.94 
1-
palmitoylplasme
nylethanolamine
* 
  
1.51 0.55 1.13 0.87 
Monoacylglycerol 
1-
linoleoylglycerol 
(1-monolinolein) 
  
0.67 0.99 1.28 1.11 
Sphingolipid 
sphinganine C00836 1.52 1.07 1.31 1.27 
sphingosine C00319 0.77 1.31 1.46 1.74 
palmitoyl 
sphingomyelin   0.6 0.84 1.04 0.84 
stearoyl 
sphingomyelin C00550 0.41 1.23 1.12 1.13 
Sterol/Steroid 
 
 
lathosterol C01189 2.98 1.51 1.1 1.47 
cholesterol C00187 0.76 0.89 1.12 0.99 
7-
dehydrocholeste
rol 
C01164 1.58 1.44 1.08 1.35 
7-alpha-
hydroxycholester
ol 
C03594 2.04 0.46 1.09 0.59 
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7-beta-
hydroxycholester
ol 
C03594 1.65 0.6 1.09 0.69 
lanosterol C01724 9.64 0.73 1.04 0.77 
Nucleotide 
Purine metabolism, 
xanthine containing 
hypoxanthine C00262 1.37 1.07 1.33 1.99 
inosine C00294 2.67 0.61 1.45 1.49 
Purine metabolism, 
adenine containing 
adenosine C00212 0.67 1.12 1.7 2.22 
adenosine 2'-
monophosphate 
(2'-AMP) 
C00946 1.04 0.99 1.2 1.43 
adenosine 3'-
monophosphate 
(3'-AMP) 
C01367 1.53 0.82 1.41 1.35 
adenosine 5'-
monophosphate 
(AMP) 
C00020 1.37 0.91 1.48 1.14 
adenosine 5'-
diphosphate 
(ADP) 
C00008 1.13 0.76 1.02 0.74 
adenosine 5'-
triphosphate 
(ATP) 
C00002 1.43 0.88 0.84 0.62 
Purine metabolism, 
guanine containing 
guanine C00242 1.01 1.28 1.31 2.07 
guanosine C00387 1.7 0.61 1.77 1.58 
guanosine 5'-
triphosphate C00044 1.67 1.13 0.83 0.77 
guanosine 5'-
diphospho-
fucose 
  
1.11 1.18 1.17 1.33 
Pyrimidine 
metabolism, cytidine 
containing 
cytidine C00475 5.69 0.23 0.72 0.56 
cytidine 5'-
monophosphate 
(5'-CMP) 
C00055 1.32 0.83 1.05 0.9 
Pyrimidine 
metabolism, thymine 
containing 
thymidine C00214 1 1 1 1.66 
Pyrimidine containing, 
uracil containing 
uridine C00299 3.26 0.71 1.33 1.37 
pseudouridine C02067 0.58 1.29 1 1.23 
uridine 
monophosphate 
(5' or 3') 
  
1.53 0.65 1.38 1.1 
uridine 5'-
diphosphate 
(UDP) 
C00015 1.25 0.74 0.95 0.7 
uridine 5'-
triphosphate 
(UTP) 
C00075 1.32 1.01 0.73 0.71 
Cofactors 
and 
vitamins 
Ascorbate and 
aldarate metabolism 
glucarate 
(saccharate) C00818 0.94 0.83 0.62 0.57 
Folate metabolism 
5-
methyltetrahydro
folate (5MeTHF) 
C00440 1.83 1.13 1.33 1.23 
folate C00504 1 1.86 1.95 4.2 
  
nicotinamide 
adenine 
dinucleotide 
(NAD+) 
C00003 0.75 1.16 0.73 0.92 
nicotinamide 
adenine 
dinucleotide 
reduced (NADH) 
C00004 1.16 0.53 1.08 0.43 
nicotinate 
adenine C00857 0.85 1.56 1.15 2.18 
80 
 
dinucleotide 
(NAAD+) 
nicotinamide 
riboside* C03150 0.89 0.48 1.25 0.61 
adenosine 
5'diphosphoribos
e 
C00301 0.3 1.1 0.88 0.94 
1-
methylnicotinami
de 
C02918 1.84 0.88 1.42 1.32 
Pantothenate and 
CoA metabolism 
pantothenate C00864 0.88 0.78 0.93 0.84 
coenzyme A C00010 1.8 0.9 0.95 0.89 
Riboflavin metabolism 
flavin adenine 
dinucleotide 
(FAD) 
C00016 1.18 1.03 1.1 1.16 
riboflavin 
(Vitamin B2) C00255 1.22 1.29 1.97 1.97 
flavin 
mononucleotide 
(FMN) 
C00061 0.72 2 1.38 2.43 
Thiamine metabolism thiamin (Vitamin B1) C00378 0.88 0.99 2.16 3.43 
Xenobiotics 
Chemical 
HEPES 
  
1.19 1.04 1.09 1.1 
phenol red C12600 1.11 1.18 1.41 1.61 
Drug penicillin G C05551 0.8 1.12 1.39 1.17 
Sugar, sugar 
substitute, starch erythritol C00503 0.59 1.05 1.04 1.05 
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Figure 23. Glycolytic metabolism in serum-starved BT-549 cells. The increase in 
glycolytic intermediates indicates that serum-starved TNBC cells utilize the Warburg 
metabolism program to subsist and grow in the face of reduced nutrient content. The 
reduction in pentose phosphate pathway intermediates indicates that TNBC cells reduce 
anabolic reactions through this pathway. ApoE4-induced rescue of serum starvation 
resulting in improved oxidative homeostasis and reduced the production of glycolytic 
intermediates to downregulate Warburg metabolism. 
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lathosterol
REG SF Apo CTRL LRP A/L
48 hours
0
0.5
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cholesterol
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48 hours
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REG SF Apo CTRL LRP A/L
48 hours
0
0.5
1
1.5
2
2.5
7-beta-hydroxycholesterol
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48 hours
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Figure 24. ApoE4-induced rescue of serum starvation resulting in reduction of 
cholesterol and fatty acid metabolites. As noted in gene expression profiling and 
confirmed in metabolic profiling, serum starvation affected levels of several cholesterol 
metabolites.  ApoE4 rescued effects of serum starvation on likely oxidative stress 
metabolites 7α-hydroxycholesterol and 7β-hydroxycholesterol and the cholesterol 
precursor lanosterol.  ApoE4 effects on cholesterol metabolism is related to the role of 
ApoE4 in regulation of cholesterol transport and metabolism.   
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inosine
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Figure 25. LRP8 knockdown reverses ApoE4-induced growth and restores pentose 
phosphate pathway. Nucleic acid metabolites, inosine, guanosine and uridine were more 
abundant in cells with serum-free media relative to regular media, and LRP knockdown 
further increased the levels of these nucleosides, while ApoE4 addition had the opposite 
effect. Intermediates to nucleotide synthesis that are components of the pentose 
phosphate pathway (ribose-5-phosphate and the ribulose-5-phosphate isobar) also had 
similar patterns.  This pattern suggests that LRP8 may block ApoE rescue by impinging 
upon the pentose phosphate pathway and reverting the cellular response to serum-free 
metabolic responses. 
Nucleic Acid Metabolites       Lipid Metabolites 
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3.19. Reduced tumor growth in shLRP8 MDA-MB-231 mouse xenografts 
shLRP8 stable knockdown cell lines were used to establish xenografts in the 
mammary glands of nude mice. Significant differences in tumor volume were observed 3 
weeks after tumor cell injection and persisted until 6 weeks after injection (Figure 26). 
The number of noted lymphovascular invasions was elevated in the shLRP8 group, in 
comparison to the one observed in the parental group (Figure 26). The percent of necrotic 
cells was significantly elevated in the shLRP8 group.  
 
 
       
Figure 26. shLRP8 MDA-MB-231 xenograft study. (A) MDA-MB-231 parental, 
shCON, and shLRP8 xenografts were established in 4 week old nude mice (n=12 per 
group). (B) Tumor necrosis as a percentage of total tumor section per slide is shown. (C) 
Tumor sections were examined for the presence of intramammary lymph node metastases 
and sectioned nodes were examined for lymphovascular invasion. Raw number count is 
depicted in the first graph. (D) Mitotic cells were counted and the mean counts were 
tested. Mean tumor quantities of the three groups were tested with one-way ANOVA 
analysis. In all panels, * indicates p<0.05 and *** indicates p<0.01.  
A B 
C D 
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Anti-LRP8  
3.20. High Ki67 and LRP8 expression in human breast tumors  
Immunohistochemical staining of LRP8 and VLDLR was performed in receptor-
negative and receptor-positive human breast tumor samples to assess the relative level of 
protein expression. 59 tumor samples were stained for LRP8 or VLDLR. For LRP8, there 
were a total of 49 IHC readings that were interpretable (13 strongly staining, 11 
moderately staining, 20 weakly staining, 5 negatively staining). 10 readings were 
discounted for the following reasons: 3 cases with no tumor cells present, 1 case with 
tissue floated, 2 cases needing H&E slide, and 4 cases with conflicting accession 
numbers between the slide label and IHC reading.  
 There were 31 grade III/IV tumors positive for LRP8 protein expression, in 
comparison to 3 grade III/IV tumors that were LRP8 negative (Table 5). The positive 
trend between high grade tumors and LRP8 protein expression did not reach statistical 
significance. High Ki67 expression was significantly associated with positive LRP8 
staining (Figure 27). 
 
 
     
 
Figure 27. LRP8 staining in human breast tumor samples. Low Ki67 expression and 
negative LRP8 staining is shown on the left tissue sample. High Ki67 expression was 
significantly correlated with positive LRP8 expression and is shown on the two right 
panels. 
        Low Ki67                              High Ki67 
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Table 5. LRP8 protein expression and its relation to clinicopathologic variables of 
breast cancer patients 
 
  Number LRP8 positive* LRP8 negative* p-value*** 
    n (%) n (%)   
All cases   49 44 (90) 5 (10)   
Age  <50 19 17 (39) 2 (40) 1 
 >50 30 27 (61) 3 (60)   
       
ER positive 25 23 (52) 2 (40) 1 
  negative 23 21 (48) 2 (40)   
  unknown 1 0 1 (20)   
       
HER2** positive 13 13 (30) 0 0.5627 
  negative 35 31 (70) 4 (80)   
  unknown 1 0 1 (20)   
       
Stage I 3 2 (5) 1 (20) 0.2343 
  II-III 45 42 (95) 3 (60)   
  unknown 1 0 1 (20)   
       
T  T0-T1 32 29 (66) 3 (60) 1 
  T2-3 16 15 (34) 1 (20)   
  unknown 1 0 1 (20)   
       
N  NX-N1 41 36 (82) 5 (100) 0.5751 
  N2-N3 8 8 (18) 0   
       
Nuclear grade I-II 14 13 (30) 1 (20) 1 
  III-IV 34 31 (70) 3 (60)   
  unknown 1 0 1 (20)   
       
Ki67**  High  24 23 (52) 1 (20) 0.025 
  Low  3 1 (3) 2 (40)   
  unknown 22 20 (45) 2 (40)   
*LRP8 positive was considered strong and moderate immunostaining on IHC. LRP8 negative was 
considered weak immunostaining. 
**HER2 positive was considered >2+ score on IHC. Ki67 high expression was considered >10% 
immunostaining. 
***p-values are based on Fisher's exact test with n ≤ 5. Two-sided, 95% confidence interval, α<0.05.
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3.21. ApoE genotyping of serum samples from human breast cancer 
Previous studies reported that genotypic expression of ApoE4 (E3/E4 and E4/E4) 
is higher in early onset breast cancer (35). To further investigate this finding, we 
compared the rate of apolipoprotein E4 carrier genotype between women with (i) ER-
negative / ER-positive breast cancer who are < 50 years and those (ii) who are >70 years 
of age. We hypothesized that ApoE4 carrier status (E4/E4, E3/E4, E2/E4) is more 
frequent among patients with young onset breast cancer compared to older patients 
women. The rate of ApoE4 carrier status was not significantly different amongst the three 
test cohorts, with 34% ApoE4 carrier status in the TNBC <50 years of age group, 28% in 
the non-TNBC <50 years of age group, and 29% in the all receptor status >70 years of 
age group (Table 6). This suggests that ApoE4 carrier status is not related to estrogen or 
progesterone receptor or HER2 status or age in the tested cohorts and that ApoE4 may be 
one signaling factor in the multifactorial development of TNBC.  
 
Table 6. Frequency of differential APOE genotype in breast cancer subpopulations 
 APOE Genotype, n (%) 
Patient group Total ApoE2 ApoE3 ApoE4 
TNBC  
<50 years of age 50 4 (8) 29 (58) 17 (34) 
Non-TNBC  
<50 years of age 50 8 (16) 28 (56) 14 (28) 
Receptor positive 
Race-matched  
>70 years of age  
50 10 (20) 26 (51) 15 (29) 
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Chapter 4 – Discussion 
________________________________________________________________________
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4.1. Target discovery and validation process 
The study investigates the LRP8 - ApoE4 receptor - ligand system in the growth 
of triple-negative breast cancer. The systematic investigation of this receptor system 
started with target identification from human breast cancer samples and led to 
experimental analysis of the growth promoting properties in vitro and in vivo. LRP8 and 
VLDLR belong to the LDL receptor family, which are most notable for their roles in 
neuronal intracellular signaling after brain injury and for cholesterol uptake and 
metabolism through LRP8 and VLDLR membrane receptors in the periphery. This study 
examines a previously defined receptor – ligand system for its role in the context of 
triple-negative breast cancer.  
 Initial identification of the overexpressed genes in TNBC was performed using 
datasets from The University of Texas M. D. Anderson Cancer Center (initial discovery, 
n = 294) and from the Erasmus Medical Center in Rotterdam the Netherlands (validation 
set, n = 286). The total patient population represents patients across all age categories, 
race, and ethnicities. The total TNBC patient population in the initial discovery set was 
73, which was comparable to the 56 patients in the validation dataset. The discovery 
dataset were comprised of fine-needle aspiration samples, which contain little or no 
contaminating stoma. These specimens represent an ideal tissue to define inherent 
molecular differences between breast cancer subsets. The additional filter (<2.0 fold 
overexpression) was introduced to confirm the initial discovery results and add 
confidence to the results obtained through sequential analysis of the initial discovery and 
validation datasets. The concurrent identification of amplified segments of DNA was 
performed for a smaller subset of 103 cases (35 of which were TNBC cases) from the   
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M. D. Anderson Cancer Center, which had matching CGH and transcriptional profiling 
results. These results confirm large-scale molecular differences between TNBC and other 
cancers. 
 Subsequent re-analysis of two additional datasets for the co-expression of the 
major ligands Reelin and APOE, receptors LRP8 and VLDLR, and intracellular adapter 
protein DAB1, was performed to assess whether the signaling system was consistently 
present across several transcriptomic datasets. This decreases the likelihood that the 
initial identification resulted in spurious results. The third database from the TRANSBIG 
study contained 170 samples, 46 TNBC and 124 non-TNBC and the fourth database from 
the Mainz study contained 178 samples, 23 TNBC and 155 non-TNBC (44, 45). The 
same interrogation of 2 cell line gene expression databases did not result in significant 
overexpression of the members of LRP8 – APOE signaling axis, however, the sample 
numbers were much lower, 51 and 19 cell lines respectively.  
 There were a number of advantages to the siRNA screen that ultimately identified 
the candidate genes that sustain the proliferation of TNBC cell lines. This high 
throughput screen has several advantages, (i) allows one to separate phenotypic markers 
from potential drivers of cancer cell growth by assessing how transient knockdown of a 
candidate gene affects growth in vitro, (ii) ability to compare growth inhibition in several 
cell lines so that an entire subset of breast cancer cell lines can be assessed to another, 
(iii) identifies key regulatory sequences in candidate genes that may serve as sites of 
downregulation in future transient or stable knockdown experimentation (based on the 
most effective siRNA target sequences), and (iv)  the resulting dataset serves as a 
functional repository of annotated genes, many of which have unknown functions in 
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cellular biology. There are limitations of a large siRNA screen that were mitigated, at 
least in part, by the data normalization methods and the optimization of the transfection 
process for each cell line described herein. 
 As previously described, LRP8 and VLDLR are family members of the LDL 
receptor family and share similar structural motifs borne from similar DNA sequences. 
The siRNA target regions for LRP8 and VLDLR were unique regions that mapped to 
independent regions of each gene, indicating that the siRNA top tier hit results were not 
duplicated based on their sequence homology. Additionally, the plasmid rescue 
experiments performed separately for LRP8 and VLDLR in 2 independent breast cancer 
cell lines helps to rule-out off-target effects and supports their independent contributions 
to TNBC cell growth. 
 Validation that the loss-of-phenotype, i.e., reduction in viability, was due to a loss 
of LRP8 and VLDLR mRNA and protein further supports that the top tier hits from the 
initial siRNA screen could be promoted to the next step of evaluation, functional 
evaluation of the role of LRP8 and VLDLR in TNBC. There were some differences in the 
optimal time point to evaluate mRNA and protein levels amongst the TNBC cell lines 
that were chosen for further validation with a standardized concentration of 50 nM of 
siRNA oligonucleotide. There were also differences in the level of target knockdown that 
was achieved. This reflects differences in the growth rate independent to each cell line in 
common use. 
 The ligand stimulation studies revealed important lessons about LRP8 signaling in 
TNBC. Reelin exposure stimulated TNBC cell growth, but to a lesser extent than the 
ApoE isoform 4. It should be noted that mouse reelin was used, as recombinant human 
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reelin was not available commercially. The central fragment that was used in cell culture 
mediates receptor binding to LRP8 and VLDLR and shares 95% sequence homology 
with human reelin. The differential binding effects of the APOE isoforms contrasted 
rather starkly to one another, with ApoE isoform 2 resulting in reduced growth and 
viability of TNBC cells and ApoE isoform 4 resulting in profound stimulation of growth 
and the overall viability of TNBC cells. To confirm that the ApoE isoform results were 
reproducible, several lots of recombinant human ApoE isoforms from 2 different 
manufacturers was used. The trend was consistent amongst different lots and protein 
manufacturer. However, there were experimental variations in viability values that were 
observed amongst the 5 replicate experiments. Lots of ApoE isoforms that were 
rehydrated and stored for longer periods of time resulted in reduced stimulation in ligand 
binding studies, suggesting that a minimal level of protein degradation occurs. 
 The ELISA binding assays between recombinant human LRP8 and ApoE4 serve 
as proof of principle that biologics may be active against the long extracellular binding 
region of LRP8. Additionally, ApoE4 stimulation resulted in robust proliferative signal at 
48 hours and the addition of RAP abolished the stimulatory effect, indicating that the two 
components compete for the LRP8 associated binding regions with higher RAP 
concentrations. RAP is not a probable candidate for therapeutic inhibition due to the 
promiscuous binding to multiple LDL receptor family members and high potential for 
off-target cardiovascular effects. Likewise, this study concentrated on the LRP8 
membrane receptor due to the restriction of its tissue distribution to the testes and brain, 
reducing the possibility of systemic off-target effects during the use of targeted 
therapeutics in most patients with breast cancer.  
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 High-throughput analyses of the ApoE4 stimulatory effects on TNBC growth 
revealed several lessons about LRP8- and VLDLR-expressing TNBC cells, (i) 
transcriptomic and metabolomic results indicate that TNBC cells amplify internal 
synthesis of steroids and lipids as energy sources and utilize glycolysis during 
environmental stress, (ii) ApoE4 restores the cell’s response to external signals and 
triggers the metabolism of supplied ApoE4, and (iii) the downstream mediators of growth 
are members of the MAPK signaling network, which integrate the ApoE4 stimulatory 
signal at the membrane surface into protein changes required for growth. Interestingly, 
human fibroblasts preferentially utilize external sources of LDL cholesterol and keep 
biosynthesis at reduced levels for energy conservation (51).  
This study is the first to investigate LRP8 – ApoE4 signaling in breast cancer. It 
supports previous findings that ApoE4 may mediate higher affinity binding to LRP8 and 
VLDLR and relates it to the activation of growth promoting signaling pathways for 
triple-negative breast cancer. The study may explain the well-documented association 
between obesity and breast cancer (52-55). It refines the existing knowledge by detailing 
that APOE genotype (ε4) may regulate LRP8- and VLDLR- expressing tumor cells in 
their unique metabolism that adapts well to nutrient-rich and serum-starved conditions. 
 
 
 
 
 
 
94 
 
4.2. Coordination of proliferative and metabolic pathways in TNBC 
 The aggressive phenotype of triple-negative breast cancer is well established (56, 
57). The disease phenotype is typified by a high rate of proliferative activity and 
increased rates of metastases. However, the underlying biology is not completely 
understood for triple-negative tumors. Two prognostic signatures comprised of 264 and 
26 probe sets were identified from supervised analysis of triple-negative breast cancers. 
IL-8-related, VEGF-related, and histone-related were identified as the major regulatory 
metagenes associated with poor prognosis (58). These signatures relate that triple-
negative tumors may be driven by high inflammatory activity and aided by low 
functioning B-cell humoral responses.  
 Oncogenic mechanisms involving AKT activation, MYC-mediated 
carcinogenesis, and MAP kinase signaling result in altered metabolic pathways that are 
specific to the cancer cell and contribute to the observation that Otto Warburg made; 
cancer cells have increased dependence on glycolysis (59). Akt mediates growth factor 
signaling to change proliferation, growth, and survival in response to changes in the 
extracellular environment. Akt is also a major regulator of glucose homeostasis and 
works by increasing GLUT1 transport, hexokinase activity, and phosphofructokinase 
activity to mediate activation of glycolysis (60). Further, AKT1 enhances Glu-4 
expression and activates the hexokinase to phosphorylates glucose to glucose 6-
phosphate in the first step of glycolysis (60). Akt may also be important in the regulation 
of de novo fatty acid synthesis, by elevating gene expression of enzymes for cholesterol 
and fatty acid biosynthesis such as ATP citrate lyase, HMG-CoA reductase, fatty acid 
synthase, and stearoyl-CoA desaturase (61). However, the transcription of these enzymes 
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requires members of the stearoyl-regulatory element-binding protein (SREBP) family of 
transcription factors. The activities of the SREBP family are mediated downstream by the 
mitogen-activated protein kinase pathway (62).  
 Myc has been implicated in the carcinogenesis of most common human cancers. 
In terms of the glycoloytic switch mechanisms, Myc activation stimulates pyruvate 
dehydrogenase kinase, isozyme 1 (PDK1) and lactate dehydrogenase A (LDH-A), which 
prevents pyruvate conversion to acetyl CoA to produce lactate (63-65). The Sp family of 
transcription factors has been shown to integrate proliferative signals and altered 
metabolism through upregulation of fatty acid synthase (FAS) through Sp1 (66). Sp1 is 
also regulates CDC25A, indicating that transcription factors may play a role in 
integrating proliferation and metabolic factors in breast cancer (66). 
Oncogenes are not the only actors in the altered metabolic schema. Tumor 
suppressor pathways support or restrict metabolic activity. For example, TP53 induces 
the expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) to inhibit 
glycolysis and shunt precursors to the pentose phosphate pathway after DNA damage, or 
represses the activity of the rate limiting enzyme of this pathway, glucose 6-phosphate 
dehydrogenase (67). p53 mutations are a frequent event in TNBC and may result in 
reduced senescence and apoptosis, which is promoted by upregulation of cyclin-
dependent kinase inhibitor 2A (CDKN2A, p16Ink4A) and inhibition of cyclin-dependent 
kinase 2 (68). The functional consequence of p53 mutations in breast cancer is still 
unclear, but a working hypothesis involves cell cycle deregulation that promotes 
accelerated proliferation and reduced DNA repair pathway mechanisms that promote 
tumorigenesis (69, 70). The coordination of multiple cellular signals require signaling 
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centers that can integrate and regulate cellular responses; Akt, p53, HIF-1, NF-κB, and 
Myc are integrators that can channel signals and orchestrate the interaction between 
proliferation and metabolic pathways (71-73).  
 The high rate of proliferation in TNBC cells, enabled by oncogenic mechanisms, 
is the basis for the metabolic differences between normal cells and cancer cells (74-80). 
High demand for cell cycle biomolecules requires a shift into anabolic metabolism, a 
transition from the normal catabolic mechanisms that breakdown glucose, fats, and amino 
acids into ATP energy-rich molecules (81-82). Signs of anabolic metabolism are high 
rates of glycolysis, the production of lactic acid, and the production of necessary 
macromolecules to be used in constructing new plasma membranes and in membrane 
remodeling as a result of increased growth factor signaling at the cellular periphery (83-
84). The ability to maximize on the limited supply of energy biomolecules through 
increased glycolytic flux and fatty acid metabolism under low nutrient and anaerobic 
conditions allows TNBC cells to grow and persist despite high energy demands and 
compromised nutrient conditions (85-86).  
 Increased glucose uptake occurs at the cellular plasma membrane and enhances 
the synthesis of cholesterol and fatty acids, nucleic acids, and the process of 
gluconeogenesis to support high energy demands of TNBC cells (87-88). The glycolysis 
pathway is the convergence point of proliferation and metabolism. TNBC cells have 
increased glycolytic flux and dependence on the Warburg metabolism to generate ATP, 
albeit inefficiently (89). To supplant this deficiency, serine biosynthesis is increased to 
fuel anaplerotic contributions of serine into the tricarboxylic acid (TCA) cycle (90).  In 
ER-negative cell lines, PHGDH is overexpressed as a result of DNA amplifications and 
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encodes for 3-phosphoglycerate dehydrogenase: the key enzyme that bridges the gap 
between glycolysis and the serine synthesis pathway (85, 86). Serine biosynthesis is 
essential for protein and nucleotide biosynthesis and further indicates that anabolic 
metabolism is important in the growth and survival of cells receptor-negative tumor cells 
with high energy demand. The detachment of MCF-10A cells from the surrounding 
matrix is energized by ATP produced from fatty acid β-oxidation and not glucose 
metabolism, suggesting that the transition from a normal cellular state to a state of cancer 
is mediated by altering the pathways for energy production and increasing the per 
molecule yield of ATP (91). The shift from epithelial to a mesenchymal phenotype 
occurs with loss of fructose-1,6-bisphosphatase (FBP1) and increased glycolytic flux and 
lactate production in TNBC cell lines (65). 
 In the clinic, there is an association between patients with triple-negative breast 
cancer and metabolic syndrome. Metabolic syndrome manifests as central obesity, insulin 
resistance, and dyslipidemia (92, 93). Experimental models using cell lines and mice 
indicate that the insulin-leptin metabolic axis is perturbed and contributes to 
tumorigenesis of breast cancer (94, 95). However, the exact mechanisms involved are 
still unclear, but the following data encapsulates what is currently known. The 
upregulation of insulin may increase breast cancer cell proliferation through insulin-
receptor signaling (94, 95). Conversely, insulin-mediated intracellular signaling may 
reduce the bioavailability of binding factors for insulin-like growth factors and 
effectively increase insulin bioavailability (94, 95). Unbound insulin in the plasma 
increases the level of insulin-like growth factor 1 (IGF-1) through positive feedback (96). 
The administration of Metformin or insulin inhibits the proliferative and colony 
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formation ability of TNBC cells, reduces tumor growth in TNBC xenograft mice, and is 
associated with reduced cancer burden in patients with type 2 diabetes mellitus (95, 97). 
The regulatory hormone for hunger, leptin, has been shown to increase hunger signals to 
the hypothalamus and increase IGF-1 receptor activity leading to increased 
phosphorylation of the leptin receptor in a feed-forward mechanism of action (95). 
Crosstalk between the IGF and EGFR pathways increased proliferation and migration of 
TNBC cells, amplifying the downstream activities of mitogen-activated protein kinases 
(MAPK), signal transducer and activator of transcription 3 (STAT3), cyclin D1, vascular 
endothelial growth factor (VEGF), and protein kinase B (Akt) (leptin). Approximately 
70% of TNBC tumors overexpress EGFR and clinical trials are currently underway that 
test the efficacy of several EGFR inhibitors (95). The combination of EGFR inhibitors 
and chemotherapeutic regimens using carboplatin plus cetuximab and 
irinotecan/carboplatin plus cetuximab has been shown to have some initial therapeutic 
value. However, there was no improvement in objective response rate, progression-free 
survival, or overall survival for metastatic TNBC patients (99, 100).  
Despite the understanding that metabolism and proliferation are interconnected, 
the critical molecular regulators of amplified proliferative activity in triple-negative 
breast cancer have not been identified. The central goal of this study was to identify and 
validate potential new targets for TNBC. In this study, LRP8 and one of its ligands, 
ApoE4, were found to stimulate breast cancer cell lines and its downregulation in TNBC 
mouse xenografts reduced tumor incidence and volume. The LRP8 – ApoE4 signaling 
axis may represent one path towards amplified proliferation and altered metabolism for 
the growth and survival of triple-negative cells. 
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4.3. Significance of LRP8 – ApoE4 signaling to TNBC tumor biology  
In light of the previously discussed results, there are genes that are important to 
proliferative signaling and activation of the metabolic switch of TNBC. The underlying 
biology that drives TNBC growth and survival integrates proliferation and metabolic 
pathways. These pathways are dependent on key regulatory genes that are currently 
untargeted.  
The identification and characterization of molecular targets of TNBC has been 
limited by (i) availability of enough TNBC cases, (ii) validation in more than one 
experimental model system, and (iii) the heterogeneity of TNBC. TNBC cases comprise 
between 20 to 25% of all breast cancer cases. Therefore, triple-negative tumors represent 
a small proportion for a given gene expression study. The recent increase of molecular 
profiling of human breast tumors has created a rich repository of gene expression data 
and enabled the discrimination of overexpressed genes in a statistical study that can be 
powered for accurate discovery. This study identified 681 genes that may contribute to 
TNBC proliferation from a discovery data set of 294 breast tumors with 73 receptor-
negative cases and a validation data set of 286 breast tumors with 56 receptor-negative 
cases. In vitro validation in multiple TNBC cell lines, MDA-MB-231 tumor xenografts, 
and additional analysis of 2 separate gene expression data sets provides a competitive 
basis to confirm the role of LRP8 in TNBC biology. TNBC tumor heterogeneity has been 
reported as one reason for the reduced efficacy of cetuximab, an anti-EGFR antibody 
(100-102). It is likely that a subtype of TNBC that overexpress EGFR is sensitive to anti-
EGFR treatment. However, the clinical success of targeting EGFR may be dependent on 
the discovery of genes that drives proliferation and contributes to altered metabolism, the 
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reproducibility of in vitro and in vivo experiments, patient selection for treatment 
regimens, and targeting the critical amplifiers of tumor growth.  
Lipid metabolism has been associated with estrogen receptor-negative breast 
cancers. Lipidomic profiling of 257 primary breast tumors identified a candidate list of 24 
genes involved in lipid metabolism (103). Several phosphocholines, 
phosphatidylethanolamines, phosphatidylinositols, and sphingomyelins were upregulated 
in ER-negative tumors of high grade (103). These membrane phospholipids are 
responsible for incorporating newly synthesized fatty acid chains into the plasma 
membrane (103). Acetyl-CoA carboxylase 1 (ACACA), stearoyl-CoA desaturase-1 
(SCD), fatty acid synthase (FASN), sterol regulatory element-binding protein 1 (SREBP-
1), and insulin-induced gene 1 (INSIG1) were highly expressed in ER-negative tumors. 
siRNA silencing of ACACA, FASN, and INSIG1 in MDA-MB-468 cells reduced cell 
viability and induced apoptosis, suggesting that lipid biosynthesis and metabolism plays a 
critical role in TNBC cell survival (103). Increased suppression of cell viability was 
observed for breast cancer cells with higher expression of lipogenic genes. Interestingly, 
siRNA-mediated reduction of proliferation was higher in MDA-MB-468 vs. MCF-10A 
cells, but the expression level of lipogenic genes was not different between cancer and 
normal cells. This suggests that (i) normal and receptor-negative cancer cells have 
different metabolic circuitry that drives growth, (ii) there are external triggers that may 
activate or inhibit lipid metabolism to modulate growth signals, and (iii) initiating target 
discovery in primary tumor samples may be more relevant to tumor biology. Further, in 
this study, ACACA, FASN, and INSIG1 were highly upregulated in low-lipid, serum-
starvation conditions, recapitulating the in vivo shift into anabolic conditions of active 
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storage of lipid biomolecules. These studies suggest that de novo fatty acid synthesis and 
membrane phospholipids restructuring occur together in ER-negative cells. Further, the 
function of fatty acid synthase (FASN) may be modulated according to metabolic needs 
during the long-course of tumor progression (104).  
In this study, LRP8 – ApoE4 signaling was identified as a potential mediator of 
environmental conditions that trigger internal metabolic changes to permit a high level of 
metabolic adaptability for growth and survival during times of reduced nutrient 
availability in TNBC cells. LRP8 – ApoE4 signaling resulted in stimulation of growth of 
triple-negative breast cancer cell lines and LRP8 silencing reduced TNBC cell growth in 
vitro and in vivo. This suggests that extracellular ligands, such as members of the 
apolipoprotein family, engage cognate lipoprotein receptors to increase cell proliferation. 
This process is regulated by the amount of nutrients in the surrounding environment. In 
low serum conditions, TNBC cells grew more slowly, exhibited signs of anabolic 
metabolism by increasing de novo synthesis of lipids by upregulation of fatty acid 
desaturase 1 and 2 (FADS1, FADS2), FASN, and LDLR, and increased the levels of key 
glycolytic intermediates (fructose-6-phosphate, fructose 1,6-diphosphate, 3-
phosphoglycerate, pyruvate, and lactate) to participate in Warburg metabolism (59, 93). 
A downstream effect is the increase in TCA cycle intermediates (succinate and fumarate). 
This process is inefficient and costly in comparison to normal oxidative respiration, 
evidenced by the increase in reactive oxygen species such as reduced glutathione (GSH) 
and the strong signature of oxidative stress. Interestingly, the levels of long chain fatty 
acids were less abundant in low serum, while the levels of medium chain fatty acids were 
increased. This suggests that the breakdown of fatty acids, fueled by the increased de 
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novo synthesis of lipids, was active and used to fuel energy demands as part of a 
metabolic response to low nutrient conditions.  
In response to the introduction of apolipoprotein E isoform 4, one of two potential 
ligands for LRP8, TNBC cells converted the intracellular signaling response. ApoE4 
stimulation downregulated many of the same members of the lipid biosynthesis family 
(FASN and LDLR), reduced levels of glycolysis and TCA intermediates, increased the 
levels of MAP2K1, and increased phosphorylation of threonine 180 and tyrosine 182 to 
activate MAPK14. The lipid biogenesis activity was centered around SREBF2, a 
transcription factor that stimulates transcription of sterol-regulated genes. The restoration 
of exogenous growth signals from ApoE4 rescued TNBC cells from a fasted state of 
serum starvation and allowed them to re-establish high levels of proliferation. This data 
suggests that triple-negative cells are capable of switching their metabolic programming 
to accomodate the absence or presence of extracellular growth factors. During times of 
low nutrient content in the extracellular milieu, triple-negative cells actively build lipids 
using acetyl-coA stores that remain in the cell to feed themselves. This anabolic process 
is temporary as cells and tissues become depleted of energy equivalents. In the body, the 
process of proteolysis and lipolysis from existing protein and fat mass eventually leads to 
extreme anabolic shock and metabolic acidosis and renal dysfunction followed by multi-
organ failure, without exogenous nutrient supplementation (starvation). However, once 
nutrients are restored, exemplified by the addition of ApoE4 to triple-negative cells, cells 
reduce their anabolic response and use the lipid signal to activate downstream signaling 
for amplified proliferation.  
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Perhaps, as a triple-negative tumor grows in mass and constructs new blood 
vessels there is a period of time whereby cells are starved of growth factors and oxygen 
(angiogenesis triple-negative). The metabolic switch into anabolism allows them to grow 
and survive for a short period of time. The arrival of growth factors and oxygen through 
newly established vessels allow triple-negative cells to re-enter catabolic metabolism. 
This metabolic adaptation enables triple-negative cells to adapt and thrive irrespective of 
the changing metabolic environment.  
The added knowledge that LRP8 – ApoE4 signaling initiates metabolic switching 
in TNBC cells (i) identifies biological mediators that integrate proliferation and 
metabolism pathways, (ii) introduces a membrane receptor – ligand pair that could be 
targeted using new or existing compounds, and (iii) contributes to the need for rational 
design of therapeutic regimens that incorporate metabolic responses. 
 
4.4. Further credentialing of LRP8-ApoE4 signaling in TNBC 
There are several limitations to this study that should be further investigated. It is 
unclear how TNBC cells function in the presence of full serum and ApoE4 ligands. There 
is some inconsistent data that suggests ApoE4 stimulation is present, but blunted in the 
presence of other ligands in full serum culture conditions. In addition, there is some data 
suggesting that miRNAs targeting ApoE contributes to invasion and metastatic 
endothelial recruitment, indicating that ApoE is an anti-angiogenic factor (miRNA 
ApoE). The elevated number of intramammary lymph node metastases and 
lymphovascular invasions were higher in shLRP8 MDA-MB-231xenografts, suggesting 
that the loss of LRP8 signaling results in reduced tumor cell proliferation, but also that 
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the loss of ApoE-mediated anti-angiogenic signaling through LRP8 increases the invasive 
potential of triple-negative tumor cells. Further, in the human body, it is unclear how 
chylomicron-bound ApoE4 associates with LRP8 / VLDLR to induce tumor cell growth 
in the mammary gland. It is also unclear whether ApoE4 dissociates from chylomicrons 
to engage LRP8 and how this occurs during fluctuating states of tumor cell growth. 
Further, the stable integration of shLRP8 in the MDA-MB-231 cell line was quite 
difficult to sustain, indicating that TNBC cells may have robust compensatory growth 
mechanisms that maintain LRP8 expression levels, which may require rational 
combinations of chemotherapy and targeted therapeutics against LRP8.  
The primary focus of future studies in TNBC utilizing the LRP8 – ApoE4 
signaling axis will be to define (i) how to target the LRP8 – ApoE4 signaling axis, (ii) the 
exact signaling mechanisms that occur after LRP8 – ApoE4 after inhibition, (iii) whether 
inhibition of signaling can reduce proliferation in vivo, and (iv) the potential effects on 
lipid biosynthesis and metabolism after inhibition. 
 
4.5. Potential impact of targeting LRP8 - ApoE4 in TNBC 
 The potential impact of targeting LRP8 signaling in TNBC revolves around the (i) 
effects on lipid and cholesterol metabolism and trafficking, (ii) off-target effects of 
tissues that express LRP8, and (iii) potential to complement existing chemotherapeutics 
and synergistically attack proliferation and metabolism.  
 There may be some effects on lipid and cholesterol metabolism. Reelin knockout 
mice display neurological defects in neuronal migration during development, decreased 
size of the cerebellum, and reduced synaptic activity (29). However, there is no indication 
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of dyslipidemias or hypercholesterolemia, suggesting that Reelin and ApoE4 signaling is 
not cooperative. Conversely, ApoE knockout mice have reduced ability to lower plasma 
cholesterol levels and develop vascular lesions (105). LRP8 was chosen as the primary 
target of this study due to its restricted tissue expression distribution in the testes and 
brain. VLDLR has a wide tissue expression distribution and is expressed throughout the 
body specifically in the liver, heart, skeletal muscle, and adipose tissue. Therefore, 
targeting LRP8 may reduce the level of off-target systemic toxicities due to the presence 
of the blood brain barrier. The potential synergistic effects of using chemotherapeutics 
and compounds targeting metabolic mediators or cholesterol have been shown for 
metastatic colorectal cancer (106, 107). A chemosensitizing effect was observed in 
myeloma and lymphoma, suggesting that the combination of existing chemotherapeutics 
and drugs targeting lipid or cholesterol synthesis may be potentially beneficial (107). 
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Appendix Table A1. ER and HER2 status of 18 breast cancer cell line panel tested 
in siRNA screen 
 
 ER status HER2 status  
Cell line GEV1 Cutoff Distribution GEV Cutoff Distribution Binary2 
11-9-1-4 7.03 N N 9.42 N N 1 
AU565 7.20 N N 15.29 P P 0 
BT20 7.53 N N 9.33 N N 1 
BT483 6.63 N N 11.52 N N 1 
BT549 7.66 N N 8.62 N N 1 
HBL100 7.15 N N 8.92 N N 1 
HS578T 6.83 N N 8.74 N N 1 
MCF7 11.45 P P 9.57 N N 0 
MDAMB157 7.10 N N 8.87 N N 1 
MDAMB231 7.32 N N 9.29 N N 1 
MDAMB361 10.70 P P 12.98 P P 0 
MDAMB435 7.76 N N 8.69 N N 1 
MDAMB436 7.16 N N 8.48 N N 1 
MDAMB453 7.75 N N 12.83 P P 0 
MDAMB468 6.94 N N 11.81 N P 0 
SKBr3 7.55 N N 14.69 P P 0 
T47D 10.14 N P 8.92 N N 0 
ZR751 10.22 P P 15.08 P P 0 
1Gene expression value 
20 = non-TNBC, 1 = TNBC 
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Appendix Table A2. siRNAs with preferential growth inhibition in TNBC cell lines   
Product.Id Product.Name NCBI.gene.symbol Gene.Description pval Num.TN.cell.line.inhibited
SI02780022 Hs_ADCY7_5 ADCY7 adenylate cyclase 7 0.017256223 6
SI00293391 Hs_AGPAT5_1 AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosph 7.07E-05 7
SI03031329 Hs_AKT3_13 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein ki 0.000349851 6
SI04199503 Hs_ANKRD11_7 ANKRD11 ankyrin repeat domain 11 0.008425566 6
SI03067568 Hs_ANXA1_11 ANXA1 annexin A1 0.001596206 6
SI04149621 Hs_APBA2_5 APBA2 amyloid beta (A4) precursor protein-binding, family A, memb 0.000202072 7
SI04138498 Hs_ARHGEF9_5 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 0.002323237 7
SI04350829 Hs_ARL4C_5 ARL4C ADP-ribosylation factor-like 4C 2.27E-06 8
SI02776956 Hs_ASNS_5 ASNS asparagine synthetase 0.002997599 5
SI04354364 Hs_ATP11A_8 ATP11A ATPase, class VI, type 11A 1.55E-05 8
SI00094066 Hs_BTN3A2_3 BTN3A2 butyrophilin, subfamily 3, member A2 0.00352236 6
SI00093681 Hs_BTN3A3_4 BTN3A3 butyrophilin, subfamily 3, member A3 4.43E-05 8
SI03038343 Hs_BTN3A3_5 BTN3A3 butyrophilin, subfamily 3, member A3 0.011282511 7
SI04375924 Hs_C11orf75_3 C11orf75 chromosome 11 open reading frame 75 0.00383842 5
SI04174002 Hs_C13orf15_2 C13orf15 chromosome 13 open reading frame 15 0.011098716 7
SI04286527 Hs_C18orf10_8 C18orf10 chromosome 18 open reading frame 10 2.26E-05 7
SI03495744 Hs_LOC727728_4 C1R complement component 1, r subcomponent 0.011261178 8
SI00027363 Hs_C1S_2 C1S complement component 1, s subcomponent 0.001147884 7
SI04278960 Hs_C21orf91_5 C21orf91 chromosome 21 open reading frame 91 6.09E-06 9
SI03190824 Hs_CALB2_6 CALB2 calbindin 2 0.000473104 6
SI04373166 Hs_CALD1_10 CALD1 caldesmon 1 0.008182397 5
SI04355764 Hs_CALU_8 CALU calumenin 6.25E-05 8
SI00104517 Hs_CAPN6_3 CAPN6 calpain 6 0.002211935 8
SI04381510 Hs_CBFB_14 CBFB core-binding factor, beta subunit 0.005021249 7
SI02777117 Hs_CBFB_9 CBFB core-binding factor, beta subunit 0.01663954 6
SI02777166 Hs_CBS_6 CBS cystathionine-beta-synthase 0.008660288 5
SI00079625 Hs_CCL8_3 CCL8 chemokine (C-C motif) ligand 8 0.000932998 7
SI02625889 Hs_CCR1_6 CCR1 chemokine (C-C motif) receptor 1 0.000224037 8
SI00024983 Hs_CCR1_4 CCR1 chemokine (C-C motif) receptor 1 0.011030667 6
SI03037419 Hs_CD44_8 CD44 CD44 molecule (Indian blood group) 0.010793521 4
SI00092946 Hs_CD86_3 CD86 CD86 molecule 0.00825734 6
SI02225720 Hs_CD97_9 CD97 CD97 molecule 0.005272821 5
SI00148498 Hs_CD97_4 CD97 CD97 molecule 0.007563179 6
SI02663941 Hs_CDH3_6 CDH3 cadherin 3, type 1, P-cadherin (placental) 0.004239063 7
SI00605087 Hs_CDKN2C_6 CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 0.00585189 6
SI00122010 Hs_BM039_2 CENPN centromere protein N 0.011778048 8
SI04331901 Hs_CHD1L_7 CHD1L chromodomain helicase DNA binding protein 1-like 0.002614413 6
SI04348799 Hs_CHST2_9 CHST2 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 0.015315573 6
SI04214217 Hs_CHST3_8 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 0.013615294 5
SI00605381 Hs_CKS1B_4 CKS1B CDC28 protein kinase regulatory subunit 1B 0.000421337 8
SI02663388 Hs_CKS2_10 CKS2 CDC28 protein kinase regulatory subunit 2 0.001922322 6
SI02660014 Hs_CKS2_8 CKS2 CDC28 protein kinase regulatory subunit 2 0.015321471 6
SI00028896 Hs_CLCN4_1 CLCN4 chloride channel 4 0.003007695 7
SI04314618 Hs_CREG1_7 CREG1 cellular repressor of E1A-stimulated genes 1 0.000735612 6
SI00355936 Hs_CSTB_2 CSTB cystatin B (stefin B) 8.07E-08 8
SI02777313 Hs_CTSC_5 CTSC cathepsin C 0.003592486 6
SI00076699 Hs_CXCL11_1 CXCL11 chemokine (C-X-C motif) ligand 11 0.004156138 7
SI00110082 Hs_CYLD_2 CYLD cylindromatosis (turban tumor syndrome) 0.006213501 7
SI00015547 Hs_CYP27A1_3 CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 0.003327216 7
SI02634100 Hs_DAPK1_8 DAPK1 death-associated protein kinase 1 0.009051367 7
SI02637950 Hs_ASK_7 DBF4 DBF4 homolog (S. cerevisiae) 0.007069086 7
SI04370639 Hs_DDX39_7 DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 0.002723352 6
SI02631132 Hs_DEK_6 DEK DEK oncogene 0.000140731 7
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SI04345383 Hs_DNAJB6_10 DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 0.003205669 7
SI03081729 Hs_DNMT1_8 DNMT1 DNA (cytosine-5-)-methyltransferase 1 0.000106911 7
SI04244394 Hs_DONSON_6 DONSON downstream neighbor of SON 5.36E-07 8
SI03138709 Hs_DSG2_5 DSG2 desmoglein 2 0.000265361 7
SI00030408 Hs_E2F3_1 E2F3 E2F transcription factor 3 8.61E-05 8
SI02638076 Hs_EHD1_6 EHD1 EH-domain containing 1 0.001997514 8
SI00379624 Hs_EN1_2 EN1 engrailed homeobox 1 0.000408735 5
SI03060771 Hs_EN1_5 EN1 engrailed homeobox 1 0.007756752 5
SI00063763 Hs_EPHB3_3 EPHB3 EPH receptor B3 3.58E-05 9
SI03249365 Hs_EPHB3_7 EPHB3 EPH receptor B3 0.009952099 6
SI02665166 Hs_EZH2_7 EZH2 enhancer of zeste homolog 2 (Drosophila) 0.004644741 6
SI04210948 Hs_FABP5_9 FABP5 fatty acid binding protein 5 (psoriasis-associated) 0.015310524 5
SI00094150 Hs_FAF1_3 FAF1 Fas (TNFRSF6) associated factor 1 0.001943792 6
SI03074771 Hs_FAM64A_3 FAM64A family with sequence similarity 64, member A 0.010284817 6
SI04287346 Hs_FANCL_9 FANCL Fanconi anemia, complementation group L 1.31E-05 8
SI02664424 Hs_FAT_8 FAT1 FAT tumor suppressor homolog 1 (Drosophila) 0.015924492 5
SI04164951 Hs_FBL_7 FBL fibrillarin 5.77E-08 7
SI00026138 Hs_FOXC1_1 FOXC1 forkhead box C1 0.014855504 5
SI04261831 Hs_FOXM1_8 FOXM1 forkhead box M1 0.006384873 8
SI04374265 Hs_FXYD6_8 FXYD6 FXYD domain containing ion transport regulator 6 0.000558756 7
SI00052766 Hs_FZD7_3 FZD7 frizzled homolog 7 (Drosophila) 0.008792018 7
SI00103614 Hs_GABRP_4 GABRP gamma-aminobutyric acid (GABA) A receptor, pi 0.001037336 7
SI04345089 Hs_GART_7 GART phosphoribosylglycinamide formyltransferase, phosphoribosyl 0.007350319 6
SI04161339 Hs_GART_5 GART phosphoribosylglycinamide formyltransferase, phosphoribosyl 0.012747425 4
SI04160065 Hs_GCSH_8 GCSH glycine cleavage system protein H (aminomethyl carrier) 0.005961711 7
SI00114639 Hs_GPRC5B_2 GPRC5B G protein-coupled receptor, family C, group 5, member B 0.000453029 6
SI03048570 Hs_GPX7_5 GPX7 glutathione peroxidase 7 0.000858056 6
SI04272961 Hs_ALF_9 GTF2A1L general transcription factor IIA, 1-like 0.013072027 6
SI04339475 Hs_GTPBP2_8 GTPBP2 GTP binding protein 2 0.011128936 6
SI02639420 Hs_GTPBP4_5 GTPBP4 GTP binding protein 4 0.001120366 6
SI00099547 Hs_GTPBP4_2 GTPBP4 GTP binding protein 4 0.014894314 6
SI00060060 Hs_GZMB_4 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associate 0.013962594 5
SI04247425 Hs_HLA-DOB_6 HLA-DOB major histocompatibility complex, class II, DO beta 2.62E-05 8
SI04435333 Hs_HLA-E_8 HLA-E major histocompatibility complex, class I, E 0.015969332 6
SI03157952 Hs_HLA-G_5 HLA-G major histocompatibility complex, class I, G 0.011367865 4
SI00445697 Hs_IFI16_4 IFI16 interferon, gamma-inducible protein 16 0.001850885 7
SI04238360 Hs_IFRD1_7 IFRD1 interferon-related developmental regulator 1 0.003231301 7
SI04193700 Hs_IFRD1_6 IFRD1 interferon-related developmental regulator 1 0.008214793 6
SI04138820 Hs_IGF2BP2_3 IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 2.28E-08 10
SI00033866 Hs_IL15RA_2 IL15RA interleukin 15 receptor, alpha 0.001087714 6
SI00605269 Hs_IRAK1_6 IRAK1 interleukin-1 receptor-associated kinase 1 0.001946072 8
SI00034104 Hs_IRF1_4 IRF1 interferon regulatory factor 1 0.00035607 6
SI04332832 Hs_ITGB1BP1_8 ITGB1BP1 integrin beta 1 binding protein 1 0.000125386 7
SI04340406 Hs_IVNS1ABP_8 IVNS1ABP influenza virus NS1A binding protein 0.001077805 6
SI00450002 Hs_JRKL_3 JRKL jerky homolog-like (mouse) 0.014231613 6
SI04338222 Hs_ANKRD15_8 KANK1 KN motif and ankyrin repeat domains 1 0.001521885 7
SI04212075 Hs_KARS_7 KARS lysyl-tRNA synthetase 0.013894209 5
SI00017885 Hs_KCNJ2_1 KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 0.00047871 7
SI00017892 Hs_KCNJ2_2 KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 0.013645724 6
SI03042858 Hs_KCNN4_6 KCNN4 potassium intermediate/small conductance calcium-activate 0.000559495 7
SI03099509 Hs_KIF4A_6 KIF4A kinesin family member 4A 0.003691331 6
SI04161381 Hs_KLF5_6 KLF5 Kruppel-like factor 5 (intestinal) 0.000759331 6
SI04281074 Hs_KLF5_9 KLF5 Kruppel-like factor 5 (intestinal) 0.004553831 5
SI00463806 Hs_KLHL21_3 KLHL21 kelch-like 21 (Drosophila) 0.003126358 7
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SI04305217 Hs_KLHL24_2 KLHL24 kelch-like 24 (Drosophila) 0.010870788 7
SI00071820 Hs_KLK7_2 KLK7 kallikrein-related peptidase 7 0.013649085 5
SI04353139 Hs_LAD1_7 LAD1 ladinin 1 2.04E-06 8
SI02780638 Hs_LAMP2_5 LAMP2 lysosomal-associated membrane protein 2 0.00427389 6
SI03067778 Hs_LBR_10 LBR lamin B receptor 0.015791542 5
SI04227076 Hs_LILRB2_8 LILRB2 leukocyte immunoglobulin-like receptor, subfamily B (with TM 0.002099815 6
SI00071043 Hs_LIMS1_3 LIMS1 LIM and senescent cell antigen-like domains 1 0.000664736 7
SI02639350 Hs_LPHN2_5 LPHN2 latrophilin 2 0.002001317 6
SI00066283 Hs_LRP8_3 LRP8 low density lipoprotein receptor-related protein 8, apolipopro 1.45E-05 8
SI03088204 Hs_LRP8_6 LRP8 low density lipoprotein receptor-related protein 8, apolipopro 0.000219115 6
SI00066269 Hs_LRP8_1 LRP8 low density lipoprotein receptor-related protein 8, apolipopro 0.001925051 5
SI03118787 Hs_LTBP1_10 LTBP1 latent transforming growth factor beta binding protein 1 0.01013516 5
SI00036505 Hs_LY75_3 LY75 lymphocyte antigen 75 1.48E-07 8
SI04157104 Hs_LY75_9 LY75 lymphocyte antigen 75 0.013131304 7
SI00605570 Hs_LYN_12 LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolo 0.013114552 6
SI00626941 Hs_MAGED4_3 MAGED4B melanoma antigen family D, 4B 0.004490425 7
SI00104251 Hs_MAPRE2_1 MAPRE2 microtubule-associated protein, RP/EB family, member 2 1.16E-05 7
SI03031812 Hs_MCAM_6 MCAM melanoma cell adhesion molecule 0.015042133 6
SI00300818 Hs_MCM4_1 MCM4 minichromosome maintenance complex component 4 0.006453696 6
SI04151119 Hs_MCM4_8 MCM4 minichromosome maintenance complex component 4 0.007935719 5
SI00629076 Hs_MCM6_4 MCM6 minichromosome maintenance complex component 6 0.001220822 6
SI04163558 Hs_MCM6_6 MCM6 minichromosome maintenance complex component 6 0.012825369 7
SI04192041 Hs_MCM7_5 MCM7 minichromosome maintenance complex component 7 0.008077136 6
SI00629692 Hs_ME1_4 ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 0.007937176 4
SI00629678 Hs_ME1_2 ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 0.008998899 7
SI04313015 Hs_ME2_8 ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial 0.016019221 5
SI02654897 Hs_MET_10 MET met proto-oncogene (hepatocyte growth factor receptor) 0.001183407 7
SI00300874 Hs_MET_7 MET met proto-oncogene (hepatocyte growth factor receptor) 0.003244267 8
SI00630805 Hs_MFGE8_3 MFGE8 milk fat globule-EGF factor 8 protein 5.53E-05 7
SI04306309 Hs_MIA_9 MIA melanoma inhibitory activity 3.84E-05 7
SI03117933 Hs_MMP7_6 MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 1.83E-05 7
SI04176788 Hs_EVA1_6 MPZL2 myelin protein zero-like 2 3.89E-05 8
SI04435900 Hs_MSH2_9 MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 0.010731906 7
SI03082856 Hs_MSLN_5 MSLN mesothelin 0.005940165 7
SI04374461 Hs_PAPD1_7 MTPAP mitochondrial poly(A) polymerase 0.00362102 7
SI04131715 Hs_NAB1_7 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 0.00260081 6
SI00133336 Hs_HCAP-G_3 NCAPG non-SMC condensin I complex, subunit G 3.30E-05 8
SI02624993 Hs_NCK2_9 NCK2 NCK adaptor protein 2 0.006942703 5
SI04218543 Hs_NDRG2_5 NDRG2 NDRG family member 2 0.00314286 8
SI04222666 Hs_NDRG2_6 NDRG2 NDRG family member 2 0.00797214 6
SI03032197 Hs_NFIB_5 NFIB nuclear factor I/B 0.005779657 7
SI04282719 Hs_NFIL3_7 NFIL3 nuclear factor, interleukin 3 regulated 0.001114907 7
SI04326686 Hs_NFIL3_8 NFIL3 nuclear factor, interleukin 3 regulated 0.00151717 7
SI04241146 Hs_NMB_7 NMB neuromedin B 0.00459353 7
SI03031889 Hs_NMI_7 NMI N-myc (and STAT) interactor 0.003836864 6
SI02662625 Hs_NMI_6 NMI N-myc (and STAT) interactor 0.009123962 7
SI00068677 Hs_NMT2_4 NMT2 N-myristoyltransferase 2 0.001107475 7
SI04893693 Hs_NRAS_11 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 0.001971218 5
SI00065205 Hs_NRTN_2 NRTN neurturin 2.56E-05 7
SI04331397 Hs_NUP88_8 NUP88 nucleoporin 88kDa 0.007950477 6
SI04180057 Hs_OAZ1_6 OAZ1 ornithine decarboxylase antizyme 1 0.007174441 8
SI04301234 Hs_OAZ1_7 OAZ1 ornithine decarboxylase antizyme 1 0.008580424 8
SI03236793 Hs_OSBPL3_5 OSBPL3 oxysterol binding protein-like 3 0.002177418 7
SI00676872 Hs_PADI2_4 PADI2 peptidyl arginine deiminase, type II 0.015436682 6
 
111 
 
SI00077266 Hs_PAPSS1_3 PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 0.002207052 6
SI04297314 Hs_PCOLCE2_7 PCOLCE2 procollagen C-endopeptidase enhancer 2 0.001594344 9
SI03097871 Hs_PDIA6_1 PDIA6 protein disulfide isomerase family A, member 6 0.002385759 6
SI00753690 Hs_TXNDC7_2 PDIA6 protein disulfide isomerase family A, member 6 0.015088553 6
SI00288071 Hs_PDXK_5 PDXK pyridoxal (pyridoxine, vitamin B6) kinase 0.005243422 6
SI04658990 Hs_PDXK_13 PDXK pyridoxal (pyridoxine, vitamin B6) kinase 0.014333326 5
SI04908953 Hs_PELI1_8 PELI1 pellino homolog 1 (Drosophila) 0.007221379 5
SI00040691 Hs_PFN2_4 PFN2 profilin 2 0.013305142 6
SI04206265 Hs_PGBD5_5 PGBD5 piggyBac transposable element derived 5 0.001160672 5
SI04252283 Hs_PGM1_6 PGM1 phosphoglucomutase 1 0.006065396 8
SI00090391 Hs_PHGDH_2 PHGDH phosphoglycerate dehydrogenase 0.013370645 3
SI00094990 Hs_PICALM_1 PICALM phosphatidylinositol binding clathrin assembly protein 1.17E-07 9
SI04210297 Hs_PITPNA_6 PITPNA phosphatidylinositol transfer protein, alpha 4.40E-08 8
SI03033289 Hs_PLAUR_5 PLAUR plasminogen activator, urokinase receptor 0.000144726 6
SI04203444 Hs_PLS3_7 PLS3 plastin 3 (T isoform) 2.20E-05 8
SI00092120 Hs_PNRC1_1 PNRC1 proline-rich nuclear receptor coactivator 1 0.001650582 7
SI04364472 Hs_POLR1E_4 POLR1E polymerase (RNA) I polypeptide E, 53kDa 0.001211935 6
SI04226474 Hs_POLR2F_9 POLR2F polymerase (RNA) II (DNA directed) polypeptide F 0.001594018 7
SI04367146 Hs_PQLC1_7 PQLC1 PQ loop repeat containing 1 0.000289096 8
SI03058517 Hs_PRKCDBP_8 PRKCDBP protein kinase C, delta binding protein 0.001238282 7
SI02659860 Hs_PRKCDBP_6 PRKCDBP protein kinase C, delta binding protein 0.017566453 6
SI03084179 Hs_PRKX_8 PRKX protein kinase, X-linked 0.000836827 7
SI04244828 Hs_PRNP_10 PRNP prion protein 0.000186998 8
SI03019324 Hs_PRNP_6 PRNP prion protein 0.015931471 6
SI02629599 Hs_PSMB2_3 PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 0.011900313 6
SI00374087 Hs_DSCR2_3 PSMG1 proteasome (prosome, macropain) assembly chaperone 1 2.50E-06 8
SI02659111 Hs_PTPLA_7 PTPLA protein tyrosine phosphatase-like (proline instead of catalyti 0.016030255 6
SI04438168 Hs_PTTG1_10 PTTG1 pituitary tumor-transforming 1 0.00060379 7
SI04148361 Hs_PUS7_1 PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) 0.002194928 6
SI04218221 Hs_QKI_6 QKI quaking homolog, KH domain RNA binding (mouse) 0.011178761 7
SI04367342 Hs_QKI_7 QKI quaking homolog, KH domain RNA binding (mouse) 0.017537111 6
SI02644509 Hs_RAP2A_5 RAP2A RAP2A, member of RAS oncogene family 0.011878709 7
SI04348757 Hs_RBM15_8 RBM15 RNA binding motif protein 15 8.74E-06 7
SI00704816 Hs_RNPC1_4 RBM38 RNA binding motif protein 38 0.000476638 9
SI03224900 Hs_DSCR1_5 RCAN1 regulator of calcineurin 1 0.010264371 5
SI02629942 Hs_RDX_5 RDX radixin 0.003640701 5
SI04162858 Hs_REXO2_2 REXO2 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 0.000975792 8
SI03106873 Hs_RNF144_8 RNF144A ring finger protein 144A 0.000674665 7
SI00706531 Hs_RPL39L_1 RPL39L ribosomal protein L39-like 0.013626946 5
SI04270399 Hs_RPP25_7 RPP25 ribonuclease P/MRP 25kDa subunit 0.000182725 7
SI04313379 Hs_RRAGD_8 RRAGD Ras-related GTP binding D 0.010720701 6
SI03112340 Hs_RRAS2_9 RRAS2 related RAS viral (r-ras) oncogene homolog 2 0.009532824 6
SI02639658 Hs_RSU1_5 RSU1 Ras suppressor protein 1 0.00071432 8
SI00710598 Hs_SAP30_2 SAP30 Sin3A-associated protein, 30kDa 0.000343097 6
SI00046319 Hs_SATB1_4 SATB1 SATB homeobox 1 0.000948557 6
SI03125605 Hs_SAV1_5 SAV1 salvador homolog 1 (Drosophila) 0.000955019 7
SI03066833 Hs_SCARB1_9 SCARB1 scavenger receptor class B, member 1 0.005543388 6
SI04171825 Hs_SCHIP1_6 SCHIP1 schwannomin interacting protein 1 0.00606721 6
SI04289684 Hs_SEH1L_10 SEH1L SEH1-like (S. cerevisiae) 0.012083626 8
SI03042613 Hs_SERPINB5_8 SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 0.013682332 6
SI02653637 Hs_SFN_5 SFN stratifin 0.000775443 5
SI04207063 Hs_SFT2D2_4 SFT2D2 SFT2 domain containing 2 3.32E-05 8
SI03113901 Hs_OPRS1_5 SIGMAR1 sigma non-opioid intracellular receptor 1 2.64E-05 9
SI00148995 Hs_PTPNS1_2 SIRPA signal-regulatory protein alpha 0.000225751 7
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SI03062647 Hs_SIRPA_1 SIRPA signal-regulatory protein alpha 0.001164226 8
SI00076727 Hs_SIX3_1 SIX3 SIX homeobox 3 0.004808197 5
SI00725529 Hs_SLC7A5_3 SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ syst 0.00376484 7
SI03046995 Hs_SMURF2_6 SMURF2 SMAD specific E3 ubiquitin protein ligase 2 0.000920045 8
SI00134302 Hs_SMURF2_3 SMURF2 SMAD specific E3 ubiquitin protein ligase 2 0.002090292 5
SI00102795 Hs_SOCS5_3 SOCS5 suppressor of cytokine signaling 5 3.11E-12 9
SI00079800 Hs_SOS1_2 SOS1 son of sevenless homolog 1 (Drosophila) 0.009557549 8
SI04212355 Hs_SOSTDC1_8 SOSTDC1 sclerostin domain containing 1 8.94E-07 9
SI00729414 Hs_SOX10_2 SOX10 SRY (sex determining region Y)-box 10 0.006505506 6
SI02758714 Hs_SRPK1_7 SRPK1 SFRS protein kinase 1 0.000805326 8
SI04438931 Hs_STK38_10 STK38 serine/threonine kinase 38 2.86E-05 8
SI02224313 Hs_STK38_6 STK38 serine/threonine kinase 38 0.000494706 8
SI04167814 Hs_STMN1_7 STMN1 stathmin 1/oncoprotein 18 0.007083201 7
SI04195002 Hs_JOSD3_4 TAF1D TATA box binding protein (TBP)-associated factor, RNA polyme 0.002612512 8
SI00012411 Hs_TAP1_1 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.64E-05 7
SI00012432 Hs_TAP1_4 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 0.000298716 7
SI00739865 Hs_TBC1D1_3 TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 0.002542705 7
SI03062073 Hs_TGFBI_6 TGFBI transforming growth factor, beta-induced, 68kDa 0.002470267 7
SI00050022 Hs_TLR2_2 TLR2 toll-like receptor 2 8.78E-05 8
SI04297804 Hs_TM4SF1_7 TM4SF1 transmembrane 4 L six family member 1 0.000363882 7
SI03225936 Hs_TMEFF1_5 TMEFF1 transmembrane protein with EGF-like and two follistatin-like 0.009027555 6
SI03211894 Hs_TMSL8_2 TMSB15A thymosin beta 15a 0.014988689 6
SI02637166 Hs_TNFAIP3_5 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 0.000984753 6
SI04191026 Hs_TPM4_6 TPM4 tropomyosin 4 0.000269152 6
SI02665075 Hs_TPX2_5 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 6.96E-05 7
SI04136342 Hs_TSPYL5_6 TSPYL5 TSPY-like 5 0.002223141 7
SI04316648 Hs_TTLL4_8 TTLL4 tubulin tyrosine ligase-like family, member 4 2.60E-07 8
SI04216681 Hs_SAE2_1 UBA2 ubiquitin-like modifier activating enzyme 2 0.000192764 8
SI04157118 Hs_UBAP2_6 UBAP2 ubiquitin associated protein 2 0.001472267 7
SI02224390 Hs_UCK2_6 UCK2 uridine-cytidine kinase 2 0.008827251 6
SI04244163 Hs_UNC84B_9 UNC84B unc-84 homolog B (C. elegans) 0.008452817 5
SI03177111 Hs_UPP1_5 UPP1 uridine phosphorylase 1 0.000211396 7
SI02664214 Hs_VCL_11 VCL vinculin 0.002924539 6
SI04143412 Hs_VGLL4_6 VGLL4 vestigial like 4 (Drosophila) 0.011180773 6
SI00051653 Hs_VLDLR_4 VLDLR very low density lipoprotein receptor 0.00177792 5
SI00051632 Hs_VLDLR_1 VLDLR very low density lipoprotein receptor 0.00211578 7
SI00051646 Hs_VLDLR_3 VLDLR very low density lipoprotein receptor 0.015091019 6
SI00060711 Hs_WARS_2 WARS tryptophanyl-tRNA synthetase 3.97E-06 6
SI00060704 Hs_WARS_1 WARS tryptophanyl-tRNA synthetase 0.015378625 7
SI00111216 Hs_WWTR1_1 WWTR1 WW domain containing transcription regulator 1 0.006067384 5
SI00111230 Hs_WWTR1_3 WWTR1 WW domain containing transcription regulator 1 0.006904822 7
SI04295858 Hs_YBX1_5 YBX1 Y box binding protein 1 0.011464614 5
SI00052003 Hs_ZIC1_2 ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) 0.009565665 7
 
113 
 
Appendix Table A3. siRNAs with preferential growth inhibition in non-TNBC cell lines 
 
Product.Id Product.Name NCBI.gene.symbol Gene.Description Gene.symbol.times
SI02778657 Hs_FNDC3B_6 FNDC3B fibronectin type III domain containing 3B 2
SI04279275 Hs_NOL1_7 NOP2 NOP2 nucleolar protein homolog (yeast) 1
SI03204922 Hs_FXYD6_5 FXYD6 FXYD domain containing ion transport regulator 6 1
SI04277553 Hs_FABP5_10 FABP5 fatty acid binding protein 5 (psoriasis-associated) 1
SI00437941 Hs_HIST1H4C_4 HIST1H4C histone cluster 1, H4c 1
SI03035221 Hs_SLC26A2_5 SLC26A2 solute carrier family 26 (sulfate transporter), member 2 3
SI00288197 Hs_RPS6KA3_6 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 1
SI00009289 Hs_L1CAM_3 L1CAM L1 cell adhesion molecule 1
SI02757762 Hs_AKT3_12 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kina 1
SI03044846 Hs_SLC26A2_6 SLC26A2 solute carrier family 26 (sulfate transporter), member 2 3
SI04199643 Hs_SLPI_5 SLPI secretory leukocyte peptidase inhibitor 2
SI04248594 Hs_SF3B3_7 SF3B3 splicing factor 3b, subunit 3, 130kDa 1
SI04311111 Hs_RHEB_10 RHEB Ras homolog enriched in brain 1
SI00345821 Hs_CHI3L1_1 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 1
SI03046554 Hs_PNRC1_7 PNRC1 proline-rich nuclear receptor coactivator 1 2
SI00114534 Hs_CYB5R2_3 CYB5R2 cytochrome b5 reductase 2 1
SI04252381 Hs_HLA-A_9 HLA-A major histocompatibility complex, class I, A 1
SI00064939 Hs_MCM2_4 MCM2 minichromosome maintenance complex component 2 1
SI04269125 Hs_SLPI_7 SLPI secretory leukocyte peptidase inhibitor 2
SI02629368 Hs_PRKCA_8 PRKCA protein kinase C, alpha 1
SI00288148 Hs_BUB1_5 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) 1
SI00448497 Hs_IQCG_4 IQCG IQ motif containing G 1
SI00081711 Hs_MSLN_2 MSLN mesothelin 2
SI04935133 Hs_SGK196_1 SGK196 protein kinase-like protein SgK196 1
SI04271918 Hs_MCM4_9 MCM4 minichromosome maintenance complex component 4 1
SI03045812 Hs_CKS1B_9 CKS1B CDC28 protein kinase regulatory subunit 1B 1
SI00012418 Hs_TAP1_2 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1
SI00719593 Hs_SLAMF8_3 SLAMF8 SLAM family member 8 1
SI04148494 Hs_LY75_8 LY75 lymphocyte antigen 75 1
SI03137190 Hs_C1orf38_5 C1orf38 chromosome 1 open reading frame 38 3
SI00645505 Hs_MIA_3 MIA melanoma inhibitory activity 1
SI00088172 Hs_HTATIP2_1 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 1
SI04318209 Hs_FLNA_10 FLNA filamin A, alpha (actin binding protein 280) 1
SI00028161 Hs_CD38_4 CD38 CD38 molecule 1
SI04144315 Hs_CDC42EP1_5 CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 1
SI02633267 Hs_EPHB3_5 EPHB3 EPH receptor B3 1
SI00088872 Hs_RAD51AP1_4 RAD51AP1 RAD51 associated protein 1 1
SI04254453 Hs_C11orf75_1 C11orf75 chromosome 11 open reading frame 75 1
SI04236519 Hs_ART3_6 ART3 ADP-ribosyltransferase 3 2
SI00038206 Hs_MX2_1 MX2 myxovirus (influenza virus) resistance 2 (mouse) 1
SI04365424 Hs_SOX10_6 SOX10 SRY (sex determining region Y)-box 10 1
SI04138988 Hs_NAB1_8 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 1
SI04247929 Hs_STEAP3_3 STEAP3 STEAP family member 3 1
SI04336164 Hs_GMPS_13 GMPS guanine monphosphate synthetase 1
SI02643326 Hs_PBK_7 PBK PDZ binding kinase 2
SI02653049 Hs_HCAP-G_6 NCAPG non-SMC condensin I complex, subunit G 1
SI00304290 Hs_ARP3BETA_4 ACTR3B ARP3 actin-related protein 3 homolog B (yeast) 1
SI03098123 Hs_CD44_10 CD44 CD44 molecule (Indian blood group) 1
SI04325664 Hs_CALML4_7 CALML4 calmodulin-like 4 2
 
114 
 
SI04249350 Hs_SERBP1_1 SERBP1 SERPINE1 mRNA binding protein 1 2
SI00299817 Hs_CDKN2A_9 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits 2
SI00432432 Hs_GTPBP2_1 GTPBP2 GTP binding protein 2 2
SI04344186 Hs_GOLT1B_5 GOLT1B golgi transport 1 homolog B (S. cerevisiae) 1
SI04234055 Hs_SAE2_2 UBA2 ubiquitin-like modifier activating enzyme 2 1
SI00045290 Hs_RARRES1_1 RARRES1 retinoic acid receptor responder (tazarotene induced) 1 1
SI02638062 Hs_MALT1_5 MALT1 mucosa associated lymphoid tissue lymphoma translocation g 1
SI04306736 Hs_HNRPH3_8 HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 1
SI04156999 Hs_PLA2G4A_7 PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 1
SI04138897 Hs_CEP57_3 CEP57 centrosomal protein 57kDa 1
SI04278799 Hs_RGL1_8 RGL1 ral guanine nucleotide dissociation stimulator-like 1 1
SI02665082 Hs_TPX2_6 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 1
SI04156089 Hs_MEMO1_1 MEMO1 mediator of cell motility 1 2
SI04320834 Hs_KHDRBS3_8 KHDRBS3 KH domain containing, RNA binding, signal transduction associ 1
SI00757799 Hs_UQCRH_1 UQCRH ubiquinol-cytochrome c reductase hinge protein 2
SI00753634 Hs_TXNDC4_2 ERP44 endoplasmic reticulum protein 44 2
SI00012824 Hs_CD59_4 CD59 CD59 molecule, complement regulatory protein 1
SI04331754 Hs_PODXL_9 PODXL podocalyxin-like 2
SI04344487 Hs_ZNF259_11 ZNF259 zinc finger protein 259 1
SI04279499 Hs_CDC5L_8 CDC5L CDC5 cell division cycle 5-like (S. pombe) 1
SI04190928 Hs_S100A10_9 S100A10 S100 calcium binding protein A10 1
SI02659503 Hs_CDKN2A_12 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits 2
SI04284350 Hs_DSG2_8 DSG2 desmoglein 2 1
SI04176452 Hs_NUP88_6 NUP88 nucleoporin 88kDa 2
SI04267746 Hs_STMN1_8 STMN1 stathmin 1/oncoprotein 18 1
SI04172910 Hs_RIF1_10 RIF1 RAP1 interacting factor homolog (yeast) 1
SI04347910 Hs_NT5DC2_2 NT5DC2 5'-nucleotidase domain containing 2 1
SI03049081 Hs_RASSF4_7 RASSF4 Ras association (RalGDS/AF-6) domain family member 4 2
SI04333042 Hs_FSCN1_7 FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus p 1
SI03180527 Hs_UBE2E3_6 UBE2E3 ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) 1
SI03068191 Hs_RFC4_8 RFC4 replication factor C (activator 1) 4, 37kDa 1
SI04355407 Hs_NUP88_9 NUP88 nucleoporin 88kDa 2
SI02664130 Hs_MSN_8 MSN moesin 1
SI00659176 Hs_NK4_4 IL32 interleukin 32 1
SI04175416 Hs_CTPS_6 CTPS CTP synthase 2
SI04239487 Hs_SLC5A6_7 SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), 2
SI00022596 Hs_ANGPT1_2 ANGPT1 angiopoietin 1 2
SI00077273 Hs_PAPSS1_4 PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 1
SI02664389 Hs_CAV2_10 CAV2 caveolin 2 1
SI03182375 Hs_UPF3B_6 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) 1
SI00114653 Hs_GPRC5B_4 GPRC5B G protein-coupled receptor, family C, group 5, member B 1
SI04167429 Hs_C1orf38_8 C1orf38 chromosome 1 open reading frame 38 3
SI00357308 Hs_CXCL10_2 CXCL10 chemokine (C-X-C motif) ligand 10 1
SI00073640 Hs_CEBPB_4 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1
SI03117660 Hs_CTSL_7 CTSL1 cathepsin L1 1
SI00129339 Hs_PLSCR1_4 PLSCR1 phospholipid scramblase 1 1
SI04192293 Hs_SLC5A6_6 SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), 2
SI04434465 Hs_SERPINH1_10 SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), me 1
SI03051930 Hs_FZD7_6 FZD7 frizzled homolog 7 (Drosophila) 1
SI04168304 Hs_MFHAS1_6 MFHAS1 malignant fibrous histiocytoma amplified sequence 1 1
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SI03170727 Hs_TTLL4_6 TTLL4 tubulin tyrosine ligase-like family, member 4 1
SI03177377 Hs_CSTB_6 CSTB cystatin B (stefin B) 1
SI00648284 Hs_MRPL15_4 MRPL15 mitochondrial ribosomal protein L15 1
SI04135712 Hs_MCM5_5 MCM5 minichromosome maintenance complex component 5 1
SI00381493 Hs_EVA1_1 MPZL2 myelin protein zero-like 2 1
SI04347721 Hs_DSC3_7 DSC3 desmocollin 3 1
SI04283615 Hs_RBM15_6 RBM15 RNA binding motif protein 15 1
SI00771708 Hs_ZNF292_4 ZNF292 zinc finger protein 292 1
SI04166239 Hs_MYBL1_10 MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 1
SI02625693 Hs_CCNE1_6 CCNE1 cyclin E1 1
SI04219726 Hs_TEX10_8 TEX10 testis expressed 10 1
SI02622284 Hs_ASK_5 DBF4 DBF4 homolog (S. cerevisiae) 1
SI00092127 Hs_PNRC1_2 PNRC1 proline-rich nuclear receptor coactivator 1 2
SI00698208 Hs_RANBP1_4 RANBP1 RAN binding protein 1 1
SI00076965 Hs_TP53BP2_4 TP53BP2 tumor protein p53 binding protein, 2 1
SI04337795 Hs_FLJ20186_8 DEF8 differentially expressed in FDCP 8 homolog (mouse) 1
SI00734188 Hs_ST5_4 ST5 suppression of tumorigenicity 5 2
SI00287798 Hs_SGK_5 SGK1 serum/glucocorticoid regulated kinase 1 1
SI03176593 Hs_IGF2BP2_1 IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 1
SI04323543 Hs_TES_8 TES testis derived transcript (3 LIM domains) 1
SI00081718 Hs_MSLN_3 MSLN mesothelin 2
SI00732935 Hs_SRD5A1_1 SRD5A1 steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha 1
SI04134151 Hs_PLAGL1_5 PLAGL1 pleiomorphic adenoma gene-like 1 1
SI04385199 Hs_SMC2_2 SMC2 structural maintenance of chromosomes 2 2
SI00113925 Hs_MTMR2_2 MTMR2 myotubularin related protein 2 1
SI04258002 Hs_BCL11A_7 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 1
SI00605584 Hs_MARCKS_5 MARCKS myristoylated alanine-rich protein kinase C substrate 1
SI03030713 Hs_CDKN2C_8 CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 2
SI04161927 Hs_PODXL_6 PODXL podocalyxin-like 2
SI02777194 Hs_SCARB1_6 SCARB1 scavenger receptor class B, member 1 1
SI00063966 Hs_EZH2_3 EZH2 enhancer of zeste homolog 2 (Drosophila) 1
SI02654064 Hs_KIF20A_7 KIF20A kinesin family member 20A 1
SI00030429 Hs_E2F3_4 E2F3 E2F transcription factor 3 1
SI04275698 Hs_GTPBP2_7 GTPBP2 GTP binding protein 2 2
SI00753648 Hs_TXNDC4_4 ERP44 endoplasmic reticulum protein 44 2
SI03099754 Hs_AK2_10 AK2 adenylate kinase 2 1
SI02662569 Hs_HMGA1_6 HMGA1 high mobility group AT-hook 1 1
SI00004571 Hs_ITGB2_3 ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 su 1
SI04194015 Hs_MEMO1_2 MEMO1 mediator of cell motility 1 2
SI02640673 Hs_TNFRSF21_6 TNFRSF21 tumor necrosis factor receptor superfamily, member 21 1
SI04355281 Hs_PHLDA1_7 PHLDA1 pleckstrin homology-like domain, family A, member 1 1
SI03171014 Hs_PLEKHB1_5 PLEKHB1 pleckstrin homology domain containing, family B (evectins) me 1
SI03106453 Hs_C3_10 C3 complement component 3 2
SI00693224 Hs_ProSAPiP1_4 ProSAPiP1 ProSAPiP1 protein 1
SI03031084 Hs_FANCA_5 FANCA Fanconi anemia, complementation group A 1
SI02654057 Hs_CCNB2_6 CCNB2 cyclin B2 1
SI04268985 Hs_RHBDL2_6 RHBDL2 rhomboid, veinlet-like 2 (Drosophila) 1
SI00079359 Hs_NFIB_2 NFIB nuclear factor I/B 1
SI00141806 Hs_RASSF4_3 RASSF4 Ras association (RalGDS/AF-6) domain family member 4 2
SI03102701 Hs_BTN3A2_6 BTN3A2 butyrophilin, subfamily 3, member A2 1
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SI00046760 Hs_CX3CL1_2 CX3CL1 chemokine (C-X3-C motif) ligand 1 1
SI04151749 Hs_CENPA_7 CENPA centromere protein A 1
SI04439708 Hs_GTSE1_9 GTSE1 G-2 and S-phase expressed 1 2
SI04434241 Hs_ASNS_8 ASNS asparagine synthetase 1
SI00104272 Hs_MAPRE2_4 MAPRE2 microtubule-associated protein, RP/EB family, member 2 1
SI04366369 Hs_LAPTM5_8 LAPTM5 lysosomal multispanning membrane protein 5 2
SI04265527 Hs_CTPS_8 CTPS CTP synthase 2
SI04366831 Hs_PFDN2_7 PFDN2 prefoldin subunit 2 2
SI04342884 Hs_DDIT4_8 DDIT4 DNA-damage-inducible transcript 4 1
SI04297573 Hs_PELI1_7 PELI1 pellino homolog 1 (Drosophila) 1
SI04214987 Hs_CALML4_6 CALML4 calmodulin-like 4 2
SI04360251 Hs_CDK2AP1_7 CDK2AP1 cyclin-dependent kinase 2 associated protein 1 2
SI03096639 Hs_FNDC3B_7 FNDC3B fibronectin type III domain containing 3B 2
SI02223977 Hs_PRKD3_5 PRKD3 protein kinase D3 1
SI04274893 Hs_ART3_7 ART3 ADP-ribosyltransferase 3 2
SI00051534 Hs_VEGF_4 VEGFA vascular endothelial growth factor A 1
SI03118745 Hs_CD97_12 CD97 CD97 molecule 1
SI04138862 Hs_ST5_5 ST5 suppression of tumorigenicity 5 2
SI03111038 Hs_ETV6_5 ETV6 ets variant 6 1
SI04229638 Hs_LAPTM5_7 LAPTM5 lysosomal multispanning membrane protein 5 2
SI04438378 Hs_DLG7_8 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 1
SI03184048 Hs_CDK2AP1_5 CDK2AP1 cyclin-dependent kinase 2 associated protein 1 2
SI04212614 Hs_HLA-E_7 HLA-E major histocompatibility complex, class I, E 1
SI03076689 Hs_C3_9 C3 complement component 3 2
SI03045910 Hs_PRKCDBP_7 PRKCDBP protein kinase C, delta binding protein 1
SI02625770 Hs_CDKN2C_7 CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 2
SI04183326 Hs_SSRP1_5 SSRP1 structure specific recognition protein 1 1
SI02223935 Hs_YES1_6 YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 1
SI03084487 Hs_SOD2_7 SOD2 superoxide dismutase 2, mitochondrial 2
SI04327260 Hs_RPIA_9 RPIA ribose 5-phosphate isomerase A 1
SI03053106 Hs_ADCY7_6 ADCY7 adenylate cyclase 7 1
SI03032512 Hs_RRAS2_7 RRAS2 related RAS viral (r-ras) oncogene homolog 2 1
SI00059458 Hs_CTSS_3 CTSS cathepsin S 1
SI04153716 Hs_SLC39A14_6 SLC39A14 solute carrier family 39 (zinc transporter), member 14 2
SI04195415 Hs_NUP93_7 NUP93 nucleoporin 93kDa 1
SI02645678 Hs_OGFRL1_7 OGFRL1 opioid growth factor receptor-like 1 1
SI03107783 Hs_SOD2_8 SOD2 superoxide dismutase 2, mitochondrial 2
SI00091630 Hs_UGP2_3 UGP2 UDP-glucose pyrophosphorylase 2 1
SI00002184 Hs_SLC26A2_3 SLC26A2 solute carrier family 26 (sulfate transporter), member 2 3
SI03057208 Hs_CASP1_16 CASP1 caspase 1, apoptosis-related cysteine peptidase (interleukin 1 1
SI04438007 Hs_PSTPIP2_9 PSTPIP2 proline-serine-threonine phosphatase interacting protein 2 1
SI04171335 Hs_TLE4_5 TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophil 1
SI00100268 Hs_KLK5_3 KLK5 kallikrein-related peptidase 5 1
SI00757813 Hs_UQCRH_3 UQCRH ubiquinol-cytochrome c reductase hinge protein 2
SI04287458 Hs_LAMP3_7 LAMP3 lysosomal-associated membrane protein 3 1
SI03038672 Hs_PTGS2_9 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H syn 1
SI04358781 Hs_CEP170_6 CEP170 centrosomal protein 170kDa 1
SI00046312 Hs_SATB1_3 SATB1 SATB homeobox 1 1
SI04324817 Hs_OSBPL3_7 OSBPL3 oxysterol binding protein-like 3 1
SI03019919 Hs_LOC146909_5 KIF18B kinesin family member 18B 1
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SI04151231 Hs_LMO4_7 LMO4 LIM domain only 4 1
SI00375956 Hs_ECHDC1_2 ECHDC1 enoyl Coenzyme A hydratase domain containing 1 1
SI03159177 Hs_OAZ1_5 OAZ1 ornithine decarboxylase antizyme 1 1
SI04291476 Hs_PFDN2_6 PFDN2 prefoldin subunit 2 2
SI04291175 Hs_KLF11_8 KLF11 Kruppel-like factor 11 1
SI04213895 Hs_CALD1_8 CALD1 caldesmon 1 1
SI02663017 Hs_CTSB_7 CTSB cathepsin B 1
SI04144959 Hs_KIAA0746_5 KIAA0746 KIAA0746 protein 1
SI00299460 Hs_BIRC5_6 BIRC5 baculoviral IAP repeat-containing 5 1
SI04183340 Hs_ARHGEF9_6 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 2
SI00146440 Hs_ABCC10_4 ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 1
SI04313351 Hs_PRAME_9 PRAME preferentially expressed antigen in melanoma 1
SI04203969 Hs_SLC39A14_8 SLC39A14 solute carrier family 39 (zinc transporter), member 14 2
SI00035588 Hs_RANBP5_3 IPO5 importin 5 2
SI04279527 Hs_ANKRD27_11 ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 1
SI04357612 Hs_LCP1_7 LCP1 lymphocyte cytosolic protein 1 (L-plastin) 1
SI04138057 Hs_PIR_7 PIR pirin (iron-binding nuclear protein) 1
SI00288526 Hs_PBK_6 PBK PDZ binding kinase 2
SI04352978 Hs_C20orf42_8 FERMT1 fermitin family homolog 1 (Drosophila) 1
SI00629104 Hs_MCM7_4 MCM7 minichromosome maintenance complex component 7 1
SI04435312 Hs_HCK_12 HCK hemopoietic cell kinase 1
SI03080154 Hs_ANGPT1_9 ANGPT1 angiopoietin 1 2
SI04311412 Hs_DDX21_7 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 1
SI02653980 Hs_SMC2L1_7 SMC2 structural maintenance of chromosomes 2 2
SI00706552 Hs_RPL39L_4 RPL39L ribosomal protein L39-like 1
SI04210689 Hs_ARHGEF9_7 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 2
SI04375868 Hs_PAK1IP1_8 PAK1IP1 PAK1 interacting protein 1 1
SI04252346 Hs_WBP5_7 WBP5 WW domain binding protein 5 1
SI00323477 Hs_C1orf38_1 C1orf38 chromosome 1 open reading frame 38 3
SI04137602 Hs_CGI-96_5 RRP7A ribosomal RNA processing 7 homolog A (S. cerevisiae) 1
SI03080175 Hs_HRASLS_5 HRASLS HRAS-like suppressor 1
SI04433954 Hs_ADA_10 ADA adenosine deaminase 1
SI04352362 Hs_PUS7_3 PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) 1
SI04256182 Hs_SERBP1_2 SERBP1 SERPINE1 mRNA binding protein 1 2
SI03100237 Hs_CENPN_3 CENPN centromere protein N 1
SI04181765 Hs_S100B_6 S100B S100 calcium binding protein B 1
SI03071285 Hs_TIMP2_8 TIMP2 TIMP metallopeptidase inhibitor 2 1
SI04212579 Hs_RRAGD_5 RRAGD Ras-related GTP binding D 1
SI00067571 Hs_ARHGEF2_4 ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 1
SI02628080 Hs_IRF1_5 IRF1 interferon regulatory factor 1 1
SI04324824 Hs_NCAPG2_3 NCAPG2 non-SMC condensin II complex, subunit G2 1
SI04265814 Hs_BBOX1_8 BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-b 1
SI04352096 Hs_DSCR2_7 PSMG1 proteasome (prosome, macropain) assembly chaperone 1 1
SI04439701 Hs_GTSE1_8 GTSE1 G-2 and S-phase expressed 1 2
SI02629592 Hs_PSMB2_2 PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 1
SI00005880 Hs_NP_4 NP nucleoside phosphorylase 1
SI00689108 Hs_POLR2F_4 POLR2F polymerase (RNA) II (DNA directed) polypeptide F 1
SI00025865 Hs_DPYSL2_3 DPYSL2 dihydropyrimidinase-like 2 1
SI00035581 Hs_RANBP5_2 IPO5 importin 5 2
SI02624986 Hs_NCK2_8 NCK2 NCK adaptor protein 2 1
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